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ABSTRACT 
               
           Receptor interacting protein kinase 1 (RIPK1) is an enzyme acting downstream of tumor 
necrosis factor alpha to control cell survival and death. RIPK1 expression has been reported to 
cause drug resistance in cancer cells; but so far, no published studies have investigated the role 
of RIPK1 in vitamin D action. In the present study, we investigated whether RIPK1 played any 
role in 1,25-dihydroxyvitamin D3 (1,25D3)-induced growth suppression. In our studies, RIPK1 
decreased the transcriptional activity of vitamin D receptor (VDR) in luciferase reporter assays 
independently of its kinase activity, suggesting a negative role of RIPK1 in 1,25D3 action. 
RIPK1 also formed a complex with VDR and deletion analyses mapped the RIPK1 binding 
region to the C-terminal ligand-binding domain of VDR.  Subcellular fractionation analyses 
indicated that RIPK1 increased VDR retention in the cytoplasm, which may account for the 
inhibition of VDR transcriptional activity. Consistent with the reporter analyses, 1,25D3-induced 
growth suppression was more pronounced in RIPK1-null mouse embryonic fibroblasts (MEF) 
and RIPK1 knockdown ovarian cancer cells than control cells. We have also shown that VDR 
was involved in RIPK1-mediated cell death pathway in a cell line specific manner. In vivo study 
showed that VDR deletion delayed the necroptotic response to tumor necrosis factor alpha in 
mice. Western blot analyses of platinum sensitive and resistant cell lines showed a correlation 
between RIPK1 expression and drug resistance, suggesting a possible role of RIPK1 in drug 
resistance. In conclusion, this study is the first to define RIPK1 as a VDR repressor, projecting 
 xi 
 
RIPK1 depletion as a potential strategy to increase the potency of 1,25D3 and its analogs for 
cancer intervention.  
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CHAPTER 1: 
INTRODUCTION 
 
1.1 Cell death  
Cell death was formulated initially as a final outcome of inflammatory tissue damage. 
However, it was later found that this is a mechanism to eliminate pathogens and regulate 
inflammation that otherwise would cause further damage of the tissue or the whole organism [1]. 
Until the nineteenth century, forms of cell death had not been classified and differentiated from 
one another. In 1972, the term “apoptosis” was first coined to define the regulated form of cell 
death which is different from inflammatory necrotic cell death [2]. Before the advent of 
molecular diagnosis of cell death events, cell death pathways were characterized mainly based on 
morphological features for several reasons. Availability of light microscopy over fluorescence 
microscopes, easiness of observations and being unable to differentiate and characterize 
seemingly similar but mechanistically different cell death pathways have put forward 
morphological classification of cell death over molecular pathway based classification of cell 
death. Since then, major cell death pathways have been termed as: 1) Apoptosis, 2) Autophagy 
and 3) Necrosis [3]. 
  
Note to reader: Portion of this chapter has been previously published in Cellular & 
Molecular Immunology (2010) 7, 243–249, and has been reproduced with permission from 
Nature Publishing Group. 
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  As it was eventually realized to be an overgeneralization to characterize cell death 
between apoptosis and necrosis on the basis of caspase dependency and independency, in 2012, 
the Nomenclature Committee on Cell Death (NCCD) has decided to classify major cell death 
pathways according to molecular mechanisms [4]. 
 
1.1.1 Apoptosis 
Apoptosis or “programmed cell death” is a form of cell death where cells decide to die 
and follow a regulated molecular events leading to its death [5].  This type of cell death was first 
demonstrated during the normal development in the nematode Caenorhabditis elegans [6, 7]. It 
soon ignited an immense interest among scientists and until recently, this type of cell death is the 
most studied among all other cell death pathways. From the birth to the death of an organism, 
apoptosis works during the development, aging, DNA damage repair, immune defense etc. in 
response to a wide variety of physiological and pathological stimuli and conditions [8]. 
Morphologically, apoptosis is defined as cell shrinkage through dense cytoplasm and more 
tightly packed organelles. In addition to that, pyknotic nuclei due to chromatin condensation is 
another prominent characteristic of apoptosis visible through light microscope [9]. Cytoplasmic 
blebbing due to separation of cell fragments and the integrity of the plasma membrane are also 
important morphological hallmarks of apoptotic cell death [9].  Despite the same morphological 
features, apoptosis has been classifieds into extrinsic and intrinsic pathways based on the 
molecular pathways it follows. Extrinsic apoptosis is initiated through the binding of death 
ligands like tumor necrosis factor (TNF), TNF-related apoptosis inducing ligand (TRAIL) or Fas 
ligang (FasL/CD95L) to their cognate receptor TNFR, TRAILR, and FAS/CD95, respectively 
[10-12]. After tumor necrosis factor-α (TNFα) binds to TNFR, the activated receptor recruits 
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proteins including Fas-associated protein with death domain (FADD) protein, which has a death 
domain (DD) in it. The receptor also recruits TNFR associated death domain (TRADD), another 
death domain containing protein [13, 14]. The death effector domain (DED) of FADD binds to 
another DED domain of caspase-8. The protein complex in the death receptor is called death-
inducing signaling complex (DISC) [14-16]. The autoactivation of pro-caspase-8 in the DISC 
cleaves downstream caspases like caspase-3, caspase-6 and caspase-7 to execute apoptosis [16, 
17]. However, apoptosis can also be induced other than external stimuli. This type of apoptosis is 
called intrinsic apoptosis. As extrinsic apoptosis is caspase-mediated, intrinsic apoptosis can be 
either caspase dependent or caspase independent [18, 19]. In intrinsic pathway, the initiation of 
apoptosis does not rely on external ligand mediated signals rather than occurs by an abundant 
cellular stress like DNA damage, oxidative stress, hypoxia, hypothermia, toxins, over-
accumulation of unfolded proteins in the endoplasmic reticulum etc. In all cases, cells can be 
either overwhelmed with the stress or fail to respond through the anti-apoptotic proteins. This 
leads to a common phenomenon called mitochondrial outer membrane permeabilization or 
MOMP [20]. The loss of mitochondrial membrane potential causes the release of cytochrome c 
along with its adaptor protein apoptotic protease activating factor, APAF1. Along with dATP 
and caspase-9, these proteins form apoptosome that initiates caspase-dependent intrinsic 
apoptotic cell death. On the other hand, release of apoptosis-inducing factor (AIF) causes DNA 
fragmentation [21]. In this caspase independent intrinsic pathway, energy depletion and 
respiratory chain inhibition are accompanied by production of reactive oxygen species (ROS). 
This also leads to apoptotic cell death [22, 23].  
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1.1.2 Autophagy  
Morphologically, autophagy is termed as a form of cell death where the cell dies through 
cytoplasmic vacuolization and degradation by lysosome [24, 25]. Due to environmental factor 
such as stress, eukaryotic cells often form a double membrane vesicle or autophagosome where 
several organelles and part of the cytoplasm are trapped. This autophagosome is later delivered 
to lysosome to be degraded [26, 27].  
 
1.1.3 Necrosis 
Although necrosis has been studied much less than apoptosis, it is the oldest form of cell 
death that had been observed and recorded and considered as an outcome of accidental cell death 
due to cellular stress. Morphologically, necrotic cell death shows plasma membrane rupture and 
dissociation of organelles [28-30]. As the plasma membrane is no longer intact, necrotic cells 
become positive for both propidium iodide (PI) and annexin V (AV) staining, differentiating it 
from the apoptotic cell death pathway [31]. Until recently, necrosis was thought to follow no 
specific molecular pathways.  
 
1.1.4 Other forms of cell death 
NCDD also denotes other forms of atypical cell death. Mitotic catastrophic cell death is 
one such type. After a failed mitosis, for example, if the daughter cell’s cytoplasm is unevenly 
distributed or has multinucleation, cell can die through apoptotic or necrotic cell death. This type 
of cell death is called mitotic catastrophe [32, 33].  On the other hand, anoikis occurs when a cell 
loses the attachment to the substrate or to another cell [34-36]. Pyroptosis is another form of cell 
death which involves the activation of caspase-1. This protein can form a protein complex called 
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“pyroptosome” which leads to interleukin-1β release. This type of cell death is observed in 
immune cells such as macrophage [37-39].   
 
1.2 RIPK family 
Receptor interacting protein 1 had been given the name since it was initially identified as 
a protein that interacts with the death domain of Fas (CD95) receptor through its C-terminal 
death domain region [40]. Eventually, it was found to be a serine/threonine kinase, hence 
alternatively called as RIP kinase 1 or RIPK1 [41]. The protein has three domains: the N-
terminal kinase domain, the intermediate domain and the C-terminal death domain. Although 
initially thought as a single protein, other proteins were later found to be structurally related to 
this protein and RIPK was hence re-named as RIP1 or RIPK1 [42]. Proteins in the RIPK family 
share a common kinase domain. RIPK2 protein has a caspase activation and recruitment domain 
(CARD) [43]. It uses this domain to bind to another CARD domain containing protein. It can 
also bind to anti-apoptotic proteins like cellular inhibitor of apoptotic proteins (cIAPs) and 
induce Mitogen activated protein (MAP) kinase and NF-κB signaling pathways [42, 44]. Other 
functions of RIPK2 include T-cell receptor regulated proliferation and IL-1β maturation [45, 46]. 
Of all the members, RIPK1 and RIPK3 share a distinctive region, the RIP homotypic interaction 
motif (RHIM). This motif is special and thought to be evolutionary conserved since only a few 
proteins possess this motif. RIPK1 and RIPK3 interact with each other through this motif [47, 
48].   
In human, RIPK4 is known as protein kinase C-δ-interacting protein kinase (DIK) and in 
mouse; it is denoted as ROV (PKK). RIPK4 is known to activate c-Jun N-terminal kinase (JNK) 
and NF-κB signaling through interaction with TNF receptor associated factor (TRAF) protein 
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[49, 50]. RIPK4 knockout mice die after birth because of abnormal epidermal development 
suggesting its key role in developmental morphogenesis [51-53]. RIPK5 protein shares structural 
similarity with RIPK4 in kinase and ankyrin repeat domains. However, RIPK5 protein’s function 
has not been fully understood yet. It has been observed that overexpression of RIPK5 induces 
apoptotic cell death through DNA fragmentation [54].   
Compared to the other members of RIPK family, RIPK6 and RIPK7 are quite different. 
Although both proteins share the similar kinase domain, they also harbor leucine rich repeat 
(LRR) motif and Ros of complex proteins or C-terminal of Roc (Roc/COR) domain. RIPK6 has 
ankyrin repeat domain whereas RIPK7 protein has a unique tryptophan-aspartic acid repeat 
domain, also known as WD40 domain. The structural similarity of these two proteins suggests 
that they might have similar role in cell signaling. Indeed, mutations in these proteins lead to 
greater susceptibility to Parkinson’s disease, although the mechanism of disease progression due 
to the mutation is still unclear [44, 55-57]. 
 
1.2.1 Domain structure of RIPK1  
Among the members of RIPK family, RIPK1 has been the most-studied protein. In 
human, it is a 671 and in mouse, 656 amino acid residue long. Despite the length similarity, these 
two proteins are only 69% identical in sequence. However, they share similar domains, each with 
specific function. The N-terminal domain of human RIPK1 is about 300 residues long, known as 
the kinase domain with an ATP binding pocket. The kinase domain has auto- and trans-
phosphorylation ability [58]. Enzyme digestion followed by mass spectrometry and in vitro  
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Fig. 1: RIPK family members and their domains  
RIPK family proteins have a common kinase domain (KD). RIPK1 and RIPK3 share a unique 
RIP homotypic interaction motif (RHIM). RIPK2 has a caspase activation and recruitment 
domain. RIPK4, RIPK5 and RIPK6 share ankyrin repeat domain (ANK). RIPK6 and RIPK7 
have unique leucine-rich repeat (LRR) and Ros of complex proteins/C-terminal of Roc 
(Roc/COR) domain which are not shared by other members of the family. RIPK7 also has WD40 
motif. 
 
 
 
Adapted from Zhang et.al. Receptor-interacting protein (RIP) kinase family; Cellular and 
Molecular Immunology (2010) 7, 243–249 with permission from Nature Publishing Group. 
Reprinted by permission from McMillan Publishers Limited: (Cellular and Molecular 
Immunology) [44] (http://www.nature.com/cmi/index.html). Copyright (2010). 
 
kinase assays revealed that the autophosphorylation sites of RIPK1. Interestingly, all 
autophosphorylation sites are in the N-terminal kinase domain. Functionally, the kinase domain 
is responsible for phosphorylating the RIPK1 protein itself and other proteins including RIPK3 
and initiating necroptotic cell death signaling. The intermediate domain is about 300 residues 
long. This domain contains a unique motif called RIP homotypic interaction motif (RHIM) 
spanning from 531 to 547 residues (Fig. 2). RIPK1 and RIPK3 bind to each other through this 
motif and hence, is important for necroptotic induction [59].  Intermediate domain is also crucial 
for ubiquitination of RIPK1 at Lysine 377 residue [60, 61]. There are other lysine residues in 
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Fig. 2. Domain structure of the RIPK1 protein 
RIPK1 protein is comprised of three domains. Each domain length has been indicated with the 
amino acid residues length shown in numbers. The kinase domain has autophosphorylation sites 
as indicated. The intermediate domain contains the RHIM motif and Lysine 377 ubiquitination 
site followed by death domain. RHIM: RIP homotypic interaction motif.  
 
RIPK1 protein which can also be ubiquitinated [62]. These sites have not been extensively 
studied and should be explored in future.  The death domain is the shortest domain of RIPK1 
protein, ranging from 583 to 671 residues. Although small in size, this domain serves as a major 
docking site for other proteins to bind to RIPK1 to conduct ligand-mediated cell survival or 
death signaling [40, 63, 64].  
 
1.2.2 Post-translational modifications of RIPK1  
The three dimensional structure of proteins is known to be changed by post-translational 
modifications [65]. These modifications not only are important for making the protein suitable 
for binding to other proteins, but also accelerate the downstream signaling process mediated by 
the protein [66]. Important post-translational modifications are phosphorylation, acetylation, 
ubiquitination, sumoylation etc. As described above, RIPK1 proteins act as an important protein 
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in cell signaling pathway. The activity of RIPK1 protein can be regulated by post-translational 
modifications like phosphorylation and ubiquitination [62].  
 
1.2.2.1 Phosphorylation of RIPK1  
Soon after its discovery, RIPK1 has become known for both its kinase activity to 
phosphorylate itself and its role as an adaptor protein in NF-κB-mediated in cell signaling. The 
kinase activity of RIPK1 is needed for necrotic induction but dispensable for TNFR-induced NF-
κB signaling [67]. The major phosphorylation sites of RIPK1 include Ser14/15, Ser20, Ser161 
and Ser166, which are considered as autophosphorylation sites [68]. RIPK1 can also be 
phosphorylated on Ser166, Ser331 and Ser416 sites. However, these sites have not been found to 
be physiologically relevant and their role in RIPK1 functions should be further investigated [69]. 
 
1.2.2.1.1 Positive and negative phosphorylation of RIPK1 
In search of potential phosphorylation sites of biological significance, various 
phosphorylation sites of RIPK1 have been mutated and the kinase or the necroptotic activities of 
the mutants have been measured. The mutation of the potential S161 site to alanine caused only a 
20% reduction in kinase activity and did not inhibit the necroptotic potential of RIPK1 [70]. 
However, S161A-RIPK1 decreased the ability of necrostatin-1 (Nec-1) to inhibit RIPK1 kinase 
activity. Collectively, most of the phosphorylation sites show additive effect on the kinase 
activity of RIPK1, negating the possibility of a single site as the sole important phosphorylation 
site. Interestingly, although Ser89 site has not been defined as a phosphorylation site of RIPK1, 
mutational analyses suggest that this site serves as a potential inhibitor of the kinase activity of 
RIPK1. S89A-RIPK1 mutant showed increased kinase activity for downstream signaling and 
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necrosome formation, indicating that the phosphorylation at residue 89, if occurs,  may 
negatively regulate RIPK1 kinase activity [69, 70]. 
 
1.2.2.1.2 Phosphorylation and necroptotic signaling of RIPK1  
Being discovered in 1995, the initial assessment about RIPK1 considered this protein to 
be only effective in apoptotic cell death. However, RIPK1 was also an important mediator of 
caspase independent non-apoptotic cell death pathway [71]. As this form of cell death had 
necrotic morphology but showed regulated cell death like apoptosis, it was coined as 
“necroptosis” [72]. This form of cell death distinguishes itself from apoptotic cell death by its 
inflammatory characteristics of necrotic cell death. The kinase activity of RIPK1 is not important 
in NF-κB signaling [73] but indispensable for the downstream cell death signaling [74, 75].  
To find out what other kinase proteins are also involved in necroptotic signaling, researchers 
from three individual laboratories performed siRNA-based screening against known kinase genes 
along with inducing cells by necroptotic signaling. The studies found out that RIPK3 was also a 
major player in this cell death pathway, which concurrently worked with RIPK1 as a binding 
partner [76-78]. It was observed that RIPK3 is an upstream regulator of RIPK1 since it can 
phosphorylate RIPK1 [77].  
 
1.2.2.1.3 Downstream effectors of RIPK1 phosphorylation   
Although it was known that the phosphorylation event of RIPK1 and RIPK3 initiates the 
necrosome formation; until recently, the downstream events of RIPK1 and RIPK3 mediated 
signaling pathway have not been defined. Sun et. al. performed immunoprecipitation with anti-
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RIPK3 followed by mass spectrometry of the bands in silver staining and found the presence of 
mixed lineage kinase domain like protein (MLKL) in the complex [79]. Further studies also 
 
 
 
Figure 3: Apoptotic and necroptotic cell death induction by TNFα and RIPK1 
Upon binding to its ligand-TNFα, TNFR recruits TRADD, TRAF2 and RIPK1 to form complex 
I. RIPK1 gets ubiquitinated by cIAPs through K63 linked ubiquitination. This can be inhibited 
by second mitochondria derived activator of caspases (SMAC) and can also be deubiquitinated 
by cylandromatosis (CYLD). This complex I further recruits inhibitor of nuclear factor kappa B 
kinase (IKK) subunits, IKKγ/NEMO (NF-κB essential modulator), to initiate NF-κB mediated 
cell survival signaling. After getting deubiquitinated by CYLD, RIPK1 binds to caspase-8 to 
induce apoptosis by forming complex IIa. If caspase-8 activity is inhibited, RIPK1 can bind to 
RIPK3 and initiate necroptotic cell death by forming complex IIb.  
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confirmed the presence of MLKL protein in RIPK1-RIPK3 complex [80, 81]. The fact that the 
kinase domain of RIPK3 was required for the binding to MLKL proteins emphasized the 
importance of MLKL as a potential target for phosphorylation by RIPK3 protein. In vitro 
phosphorylation assays also confirmed that MLKL got phosphorylated by RIPK3, but not by 
RIPK1 [82]. The major phosphorylation sites of murine MLKL are Ser345, Ser347 and Thr349, 
which correspond to human Thr357 and Ser358 sites [83, 84]. A potential inhibitor of 
necroptosis, necrosulfonamide, was found to bind to MLKL and inhibit necroptosis through the 
binding, further confirming that RIPK3-MLKL interaction drives necroptosis. After 
phosphorylation, RIPK3-MLKL complex is translocated to the membrane and causes membrane 
depolarization. The phosphorylation of MLKL is indispensable in membrane translocation since 
the mutant proteins were unable to translocate to the plasma membrane and induce necroptosis 
[80]. 
 
1.2.2.2 Acetylation of RIPK1 
Acetylation of protein refers to the addition of an acetyl group to mostly lysine residues 
of the protein. It is a major post-translational modification for nuclear proteins like histones and 
transcriptional regulators [85]. Most of the proteins involved in energy metabolism pathways like 
glycolysis, TCA cycle, urea cycle, chromatin remodeling, cell cycle, splicing, nuclear transport, 
actin nucleation, and mitochondrial metabolism etc. are known to be acetylated, which renders 
this modification a major role in metabolic pathways [86]. Histone modifications by acetyation  
also change nuclear conformation, thereby influencing transcription. As acetylation changes the 
activity and stability of these enzymes, it is as important as other post-translational modifications 
like phosphorylation or ubiquitination. On the other hand, deacetylation of proteins is also 
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important as the event also changes protein’s structure and shape and thereby, changes their 
functions. Sirtuin 2 (SIRT2) is a nicotinamide adenine dinucleotide (NAD+) dependent 
deacetylase that was suggested to play an important role in necroptotic signaling process. 
Narayan et.al. initially showed that SIRT2 binds to RIPK3 and deacetylates RIPK1, which was 
required for the formation of RIPK1-RIPK3 complex to induce necroptosis. They also showed 
that SIRT2 inhibitor blocked RIPK1-RIPK3 complex formation and necroptotic induction and 
that SIRT2-/- cells were not responsive to necroptotic cell death induction, suggesting that 
SIRT2 was required for necroptosis [87]. However, their work was challenged by multiple 
research groups who failed to reproduce the data. Additionally, SIRT2 -/- mice died of 
necroptotic cell death after tail-vein TNFα injection, suggesting that SIRT2 is dispensable in 
necroptotic cell death [88]. This controversial issue was addressed by a more recent paper 
showing that SIRT2 was indeed required for necroptosis. However, this group also introduced 
another member, SIRT5, of the same SIRT family as a potential protein to induce necroptosis 
redundantly with SIRT2. The reason that SIRT2 knockdown did not inhibit necroptosis in some 
cell lines was the functional redundancy played by SIRT5, which was initially ignored. This 
might also explain why SIRT2-/- died of necroptotic cell death after TNFα injection [89].   
 
1.2.2.3 Ubiquitination of RIPK1  
RIPK1 was first implicated in TNFα-stimulated NF-κB activation. Since RIPK1 itself is a 
kinase, its phosphorylation activity towards itself or other proteins was first assumed to be the 
activating factor. However, RIPK1 was also assumed to have further covalent modifications 
other than phosphorylations for several reasons. First, the phosphorylation of inhibitor of kappa 
B (IκB) kinase (IKK) was not efficient by RIPK1 itself. On the other hand, kinases present in the 
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whole cell complex were more capable of phosphorylating the IKK proteins. Therefore, RIPK1 
was not involved in phosphorylating IκB kinase proteins. SDS-PAGE analyses of the TNFR 
complex also showed a ladder-like appearance of RIPK1 protein, which is a feature of 
ubiquitinated protein. Overexpression studies of RIPK1 in Jurkat cells stimulated with TNFα 
followed by immunoprecipitation of RIPK1 showed that RIPK1 gets ubiquitinated. Of the five 
consecutive lysine residues in the intermediate domain of RIPK1, each one was mutated  to find 
out the specific ubiquitination site. The analyses showed that RIPK1 gets exclusively 
ubiquitinated at the lysine 377 site [60].  Mutational studies with of mutant ubiquitins showed 
that RIPK1 gets ubiquitinated through K63-linked ubiquitin chain. This polyubiquitination chain 
of RIPK1 recruits the member of IKK family, IKKγ or NEMO. Both the polyubiquitination of 
RIPK1 and the binding of NEMO are important for NF-κB activation. Polyubiquitination of 
RIPK1 by K63-linked chain also recruits and activates transforming growth factor beta (TGFβ) 
activated kinase (TAK1) protein through TAK1 binding protein (TAB) TAB2 and TAB3, which 
preferentially bind to K63-linked polyubiquitnated RIPK1 [71].  
 
1.2.3 Ubiquitination in NF-κB signaling  
Addition of ubiquitin to protein is called ubiquitination or ubiquitylation. Ubiquitin is a 
small protein of 76 amino acid residues and of 8.5kDa in molecular weight. It is a highly 
conserved protein found to be unique in eukaryotes [90-92]. The C-terminus of the ubiquitin 
covalently linked to the N-terminal end or the N-group of a lysine residue of the substrate. Of the 
ubiquitin’s 76 residues, 7 are lysine residues that can be used to form polyubiquitin chains with 
other ubiquitin proteins. The ubiquitination process depends on three consecutive steps. 1) 
ubiquitin activation, 2) ubiquitin conjugation and 3) ubiquitin ligation. The ubiquitin activating 
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enzyme (E1) catalyzes the reaction of thioester linkage formation between ubiquitin. Ubiquitin 
conjugating enzyme (E2) catalyzes the binding of activated ubiquitin to itself. In the final step, 
ubiquitin ligase enzyme (E3) catalyzes the reaction of the binding between the lysine residue of 
the target protein and the C-terminal glycine residue of ubiquitin [90, 93, 94].   
Different types of ubiquitination can occur in proteins. Monoubiquitination occurs when 
only one ubiquitin protein binds to the substrate protein. Multiple monoubiquitination occurs 
when ubiquitin binds to multiple sites of the protein. Polyubiquitination occurs when ubiquitin 
binds as a linear or branched pattern through its 7 lysine residues (Lys6, Lys11, Lys27, Lys29, 
Lys33, Lys48 or Lys63). Different types of polyubiquitination are defined according to the lysine 
residues of the ubiquins used for the for4mation of polyubiquitin chains. For example, K48 
ubiquitination is called if the connecting ubiquitin is attached to the Lys48 residue of the 
previously attached ubiquitin, and K63 ubiquitination is used if the incoming ubiquitin is 
attached to the Lys63 residue of the previous ubiquitin [90, 93]. Different types of ubiquitination 
are used in different molecular pathways. Monoubiquitination of proteins usually leads to protein 
trafficking, endocytosis and DNA repair [95]. K48 linked polyubiquitination signals mainly for 
proteolytic cleavage of the protein whereas K6, K28 and K63 polyubiquitination signals for non-
proteolytic activation, such as kinase activation or the activation of NF-κB mediated cell survival 
pathway [94]. The length and types of the ubiquitin chain determine the outcome of the 
ubiquitinated protein.  
 
One function of ubiquitination is to make the protein available for binding by other 
proteins. Proteins bind to the ubiquitinated protein through ubiquitin binding domain (UBD) 
[96]. UBD comprises of a diverse structure including zinc fingers and plekstrin homology motif, 
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which allows the flexibility and choice of binding proteins to target ubiquitinated proteins. A 
single protein can bind to multiple ubiquitination sites of another protein. Alternatively, two 
different proteins can bind to different ubiquitination sites of the same protein. In both cases, this 
binding results in the activation of a downstream signaling pathway to amplify the signal. 
Ubiquitinated proteins signal different outcomes through differently linked chains. Generally, 
K63-linked ubiquitination signals for cell survival whereas K48-linked ubiquitination targets 
proteins for proteasomal degradation [97]. 
 
1.2.4 RIPK1 ubiquitination is important for cell survival  
As RIPK1 deficient mouse embryonic fibroblast (RIPK1-/- MEF) are highly sensitive to 
TNFα-induced cell death, it underscores the fact that the presence of RIPK1 is important for cell 
survival [98]. However, whether RIPK1 ubiquitination is also important or not has remained 
unknown for a while. To investigate this question, RIPK1 ubiquitin mutant construct (RIPK1 
K377R) was generated and stably expressed in RIPK1-deficient cells. It was observed that 
RIPK1-K377R expressing cells were more susceptible to TNFα induced apoptotic cell death than 
cells expressing wild type RIPK1. Therefore, the ubiquitination of RIPK1 appeared important for 
cell survival [60].  
 
1.2.5 RIPK1 as a survival protein  
Besides being a kinase, RIPK1 can serve as an adaptor protein in cell signaling pathways. 
As discussed, diverse death ligands bind to their corresponding receptors and recruit adaptor 
proteins, including RIPK1. RIPK1 serves as the cross-road between the decision of life and death 
of the cells depending upon the interplay between the cell survival and cell death signaling 
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complexes [71]. RIPK1 mainly forms complexes with cell surface receptors after stimulation 
with death ligands. The initial assessment of RIPK1 protein in chemotherapeutic treatment was 
that, this protein can be used for killing of cancer cells by death ligands. Induction of pro-
apoptotic or pro-necrotic complex like “Ripoptosome” or the RIPK1-RIPK3-caspase-8 complex 
seemed to be a promising target for chemotherapy [99, 100]. RIPK1-/- die shortly after birth 
through apoptotic cell death in major adipose and lymphoid tissues, indicating the role of RIPK1 
in cell survival [98].  This also may be the case in cancer cell survival. Recent studies have 
shown that RIPK1 is upregulated in melanoma cells than normal skin cells [101]. This 
upregulation helped the melanoma proliferation since stable knockdown of RIPK1 in those 
melanoma cells inhibited the proliferation. The survival function is also supported by the fact 
that ectopic expression of RIPK1 increased melanoma cell proliferation and induced anchorage-
independent melanocyte growth. The same group has also shown that RIPK1 is increased in 
endoplasmic reticulum stress by tunicamycin or thapsigargin treatments, which allows melanoma 
cells to survive and evade apoptosis by going through autophagy [102]. Knockdown of RIPK1 
significantly decreased melanoma cell survival, which corroborated their earlier findings. 
Another study has also shown that RIPK1 serves as a chemoresistance inducing protein in lung 
cancer cells. Wang et.al. has shown that in RIPK1 knockdown lung cancer cells, the cytotoxic 
effect of cisplatin was significantly increased, suggesting that RIPK1 helps cancer cells to 
survive through chemotherapeutic treatment [103]. Current chemotherapy involves drugs that 
induce apoptosis in cancer cells by inducing reactive oxygen species (ROS) generation. Cancer 
cells have evolved mechanisms to subvert the effect of ROS by inducing antioxidant expression 
like catalase. It has also been observed that in RIPK1 knockdown cells, both the stability and 
synthesis rate of catalase were decreased. Further investigation in this pathway also led to the 
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finding that micro-RNA 16a expression was increased in RIPK1 knockdown cells, which targets 
catalase and degrades the protein. Therefore, this work summarizes a novel role of RIPK1 in 
cancer cell survival and shows how cancer cells can evade apoptosis through RIPK1 by inducing 
microRNA regulated catalase degradation.   
 
1.2.6 Regulated necrosis or necroptosis  
Apoptosis and necrosis had shown a distinct features in terms of initiation and 
morphological features. As mentioned earlier, while apoptotic pathway has already been well 
established to be regulated, necrosis was thought to be a totally unregulated event with 
physiologically catastrophic consequences. In addition to that, apoptosis and necrosis were 
thought to be initiated by different inducers until 1988 when Laster et.al. showed that both 
apoptosis and necrosis could be initiated by a single death ligand, TNF [104]. This group noticed 
that in response to TNF induction, F17 cells showed apoptotic cell death whereas L-M cells went 
through necrosis. This indicated that the type of cell death by TNF may depend on the types of 
cells. It was known that TNF induced necrotic cell death in L929 cells[105].  Interestingly, in the 
presence of caspase inhibitor, the TNF accelerated necrotic cell death to L929 cells[106]. This 
led to the notion that necrosis can also be triggered or regulated like apoptotic cell death 
pathway. However, to show a true regulation of necrotic cell death pathway, proteins that play 
roles in that event were yet to be identified. In 2000, Holler et. al. first showed that in caspase-8 
inactivated T cells, FasL caused necrotic cell death. However, this type of FasL induced cell 
death was not observed in T cells lacking RIPK1 and FADD proteins [107]. This study first 
showed that RIPK1 and FADD are required for necrotic cell death pathway. Since this form of 
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cell death showed necrotic morphology yet showed regulated pathway like apoptosis, Degterev 
et.al. termed this type of cell death as “Necroptosis” [72].  
 
1.2.6.1 Necroptosis is a kinase-mediated pathway  
Myocardial infarction and cerebral ischemia are examples of acute physiological 
conditions where human tissues have necrotic cell death. As a subset of necrotic cell death is 
regulated event like necroptosis, a drug preventing necroptosis can be an acceptable treatment 
method for the patient. In search of a potential target for treating necrotic cell death, Degterev 
et.al. screened ~15,000 potential compounds and found necrostatin-1(Nec-1) to be a potent 
inhibitor of necroptotic cell death induced by death ligand [68]. Additionally, Nec-1 did not 
change the morphology of apoptotic cell death process, confirming that it exclusively works on 
necroptotic cell death [68, 108]. More importantly, Nec-1 significantly inhibited in vivo ischemic 
neuronal injury, suggesting it to be a potential drug candidate for inhibiting necrotic cell death 
related diseases [72]. Like other kinase inhibitors, Nec-1 has an indole ring that makes it an ideal 
kinase inhibitor. In vitro kinase assays showed that Nec-1 significantly decreased RIPK1 kinase 
activity. Structure-activity relationship analyses also concluded that Nec-1 specifically targets 
RIPK1[68]. Although RIPK1 was originally identified as the key protein in necroptosis, further 
research showed that necroptosis is indeed mediated by RIPK1 and RIPK3 complex [76-78]. 
 
1.2.6.2 RIPK3 is a necroptotic switch   
As mentioned earlier, RIPK1 protein can act both in cell survival and cell death 
pathways. Although the kinase domain of RIPK1 is not required for NF-κB-mediated cell 
survival pathway, it is required for RIPK1 mediated cell death pathways. Although the kinase 
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activity of RIPK1 is generally required for necroptotic cell death, it is not the determinant of 
necroptosis in all cell lines [109]. Therefore, other proteins must be involved in necroptotic 
induction. It has already been known that z-VAD is a pan caspase inhibitor and, SMAC mimetic 
(SM) inhibits the anti-apoptotic functions of cIAP proteins [100, 110]. Therefore, treating cells 
with TNFα and SM induce apoptotic cell death in the absence of z-VAD. If z-VAD is added, 
caspase mediated apoptotic cell death is inhibited and accordingly, TNFα/SM co-treatment 
induces necroptotic cell death. A genome wide screening of siRNA pool in FADD-deficient 
Jurkat and human colorectal carcinoma HT-29 cells showed that the knockdown of RIPK3 also 
decreased necroptotic cell death induction along with RIPK1 knockdown as a positive control. 
On the other hand, the knockdown of the other members of RIPK family did not alter cell 
viability [76]. From previous studies, it was already known that RIPK1 and RIPK3 share 
common domains and bind to each other [47]. Furthermore, in RIPK3 stable knockdown cell 
line, TNFα/SM/z-VAD induced necroptotic death was abolished. Together, these data suggest 
that RIPK3 is the molecular activator of necroptotic cell death. RIPK3 is not expressed in all cell 
lines. A cellular expression profile of RIPK3 among mouse and human cell lines along with their 
necroptotic response showed that only those cells that express RIPK3 responded to necroptotic 
induction [76]. Compared to RIPK3, RIPK1 is ubiquitously expressed in different cell lines, 
further confirming that RIPK3, not RIPK1, is the molecular switch to necroptosis from 
apoptosis. The kinase activity of RIPK3 is also important in necroptosis. Although RIPK1 has 
autophosphorylation capability, no phosphorylation was observed in TNFα-treated RIPK3-/- 
MEF cell line, indicating that RIPK3 is required for RIPK1 phosphorylation and works upstream 
of its phosphorylation event [77].  
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1.2.7 Pathological consequences of necroptotic protein knockout in mice   
Functions of proteins may vary in different developmental stages of an organism. This 
notion was more established when the physiological effect of the knockout mice of different 
important genes was generated. Kelliher et.al. showed that RIPK1-/- mice died perinatally within 
3 days of birth [98]. This showed that RIPK1 is important for perinatal development of mice. 
This study is in the striking contrast with the established idea that RIPK1 is required for caspase-
8 mediated apoptosis and RIPK3 mediated necroptosis [100]. However, further knockout models 
show that during development, RIPK1 works to inhibit both cell death pathways [111, 112]. As 
mentioned earlier, RIPK1-/- mice do not survive beyond 3 days of birth. On the other hand, 
knock-in mice carrying the kinase-dead mutant (D138N or K45A) of RIPK1 survive to 
adulthood [113, 114]. Therefore, it is not the kinase activity, rather than the structural role of 
RIPK1 that is required for the survival of the embryo and the development of mice. Tissues of 
RIPK1-/- mice show apoptotic cell death in histological assays [98]. It is already known that 
although RIPK3-/- mice are viable, RIPK1(-/-)/RIPK3(-/-) double knockout mice show perinatal 
death.  As observed in earlier studies, caspase-8 null mice died at embryonic day 10.5. RIPK1 
and caspase-8 double knockout mice survived further and died within 1 day of birth [115, 116]. 
This indicates that RIPK1 is not responsible for the death of caspase-8 null mice at E10.5.  On 
the other hand, RIPK1/RIPK3/caspase-8 and RIPK1/RIPK3/FADD triple null mice survive. This 
supports that RIPK1 may be required to prevent the FADD and caspase-8 mediated apoptotic 
cell death at the time of birth [116]. 
Although RIPK1 and RIPK3 work together in necroptotic cell death pathway, the role of 
RIPK3 in developmental pathway seems different from RIPK1 [116]. Different from RIPK1-/- 
mice, RIPK3-/- mice survive to adulthood [114]. However, this type of mice is not responsive to 
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in vivo necroptotic induction, corroborating the role of RIPK3 in necroptosis [117]. In addition, 
whereas RIPK1 kinase dead mutant mice survived to adulthood, RIPK3 D161N (kinase dead 
mutant) mice did not. Interestingly, RIPK3 D161N (kinase dead mutant)/caspase-8-/- mice 
survived to adulthood [114, 118]. Since caspase-8-/- mice die at the same gestation period, the 
survival of RIPK3 D161N (kinase dead mutant)/caspase-8 -/- mice suggests that RIPK3 and its 
kinase activity are responsible for the death of  caspase8 deficient embryos [114].   
 
1.2.8 In vitro and in vivo induction of necroptosis  
In cells, cIAP protein family acts as a checkpoint to control unintended apoptosis. cIAPs 
have ubiquitin ligase activity and keeps RIPK1 K63 ubiquitinated so that NFkB cell survival 
pathway is active. However, if cIAPs are inactivated by intracellular proteins or chemicals like 
SM, this checkpoint is compromised. Therefore, etoposide or SM can inhibit cIAPs and turn the 
TNFα-mediated cell survival pathway into cell death pathway. This cell death pathway can be 
both apoptotic or necrotic. In addition to TNFα, SM and z-VAD can inhibit caspase-8 mediated 
apoptotic cell death and direct the cell death to necroptosis. Therefore, the combination of TNFα, 
SM and z-VAD is used to induce necroptotic death in vitro in cells. However, in cell lines like 
L929 where TNFα is produced in an autocrine manner, TNFα alone is sufficient to  induce 
necroptosis without z-VAD and SM.  On the other hand, induction of necroptosis in vivo in mice 
is pretty straightforward. It has been observed that injecting TNFα in mice can provoke systemic 
inflammation as compared to systemic inflammatory respiratory syndrome (SIRS). However, 
addition of z-VAD sensitizes mice to TNFα more than TNFα alone [117, 119].  
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1.2.9 Necroptosis and inflammation  
Inflammation is considered to have four hallmark signs as: color, calor (heat), rubor 
(redness), tumor (swelling), and dolor (pain) [120, 121]. Although inflammation was initially 
thought as a result of injury, now it is considered as a process of tissue repair. Rather than just 
mechanical insults to body, inflammation is now being considered as an event mediated by host 
cell itself [121]. Inflammation and cell death are integral to each other since the same receptor 
proteins involved in inflammation are responsible for cell death signaling as well. On the other 
hand, cell death processes lead to inflammation as well.  The major host cell mediated 
inflammatory mechanisms include the rupture of blood and lymphatic vessels [122] and the 
release of host cell secreted molecules like hydrogen peroxide to induce inflammation on 
neighbor cells [1, 123].  Dying cells in tissues secrete cytokines including TNF, CD95L (FasL), 
TRAIL, interferon, etc., which bind to neighbor cells and decrease the cell survival signal to 
initiate inflammatory signaling, leading to cell death [120]. Of the known cell death pathways, 
apoptosis has more of a positive and resolving role in suppressing inflammation. It has been 
observed that neutrophils in inflammatory sites are engulfed by macrophages to reduce 
inflammation [124]. In addition to that, apoptotic cells expose phosphatidyl serine that helps 
phagocytes to be attracted to engulf the dying cells [125-127]. However, the role of apoptosis in 
inflammatory is not always suppressive. During late apoptosis, plasma membrane rupture is also 
evident. Therefore, the release of damage associated molecular patterns (DAMPs) also causes 
inflammation [128]. It is also known that apoptotic cancer cells after chemotherapeutic treatment 
can cause inflammation [129]. However, necroptosis has always been thought to be more 
inflammatory than apoptosis since the plasma membrane rupture causes massive DAMP to be 
released, which attracts inflammatory cells [130]. Both apoptotic and necroptotic cells are 
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eventually phagocytosed. However, given the amount of DAMPs secreted outside, it is clear that 
necroptotic cells trigger more inflammation. Recent study shows that necroptosis in 
keratinocytes is more inflammatory than apoptosis [111]. 
 
1.3 Nuclear receptor superfamily 
From single cell bacteria to about 37 trillion cell-containing organism like human, gene 
expression regulation is an integral part of the central dogma of life [131]. Nuclear receptors 
have been an indispensable playmaker in this gene regulation having their ability to bind directly 
to DNA. Soon after the discovery of DNA structure, the concept and discoveries of gene 
regulators started gaining scientist’s attention, and the field of research on nuclear receptors is 
growing with a fast pace since then [132]. It has been almost thirty years since the first isolation 
of the cDNA of glucocorticoid, thyroid and estrogen receptors [133-135]. Since then, significant 
discoveries have been accomplished in nuclear receptors. These receptors along with their ligand 
showed that chemically different ligands can bind to structurally related receptors. Specially, the 
first discovery of receptor for vitamin A gave a clue to scientists about the reality of a nuclear 
receptor superfamily [136, 137].  Along with the ligands for receptors, the receptor’s ability to 
form homo or heterodimers gave the whole nuclear receptor superfamily an immense 
opportunity to play a role in diverse molecular pathways including homeostasis, reproduction, 
metabolism and development [132, 138].  
           Although initially thought merely functioning as transcription factors, nuclear receptors 
also function as signal transducers. Different organisms contain different number of 
phylogenetically related nuclear receptor proteins. The fly Drosophila melanogaster contains 21 
genes, human contain 48 genes and surprisingly, Caenorhabditis elegans contains 270 genes 
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[139-141]. The high number of C. elegans is possibly due to the proliferation and diversification 
of the genes [141]. The ligands of the nuclear receptor are fat-soluble lipophilic steroid hormones 
having a high affinity to their receptors and originated exclusively from endocrine sources. 
Unlike their peptide hormone counterparts, these steroid hormones can get through the plasma 
membrane’s lipid bilayer due to their lipophilic nature and bind to their respective receptors in 
the cell [142-144].  
 
1.3.1 Nuclear receptor family classification 
The nuclear receptor superfamily has been divided into 4 classes according to their DNA 
binding characteristics and the mode of dimerization.   
Type I receptors are classical steroid hormone receptors such as glucocorticoid receptor 
(GR), mineralocorticoid receptor  (MR), estrogen receptor (ER), androgen receptor (AR) and 
receptor progesterone (PR). These receptors form homodimer and bind to palindromic sequences 
with inverted repeats separated by 3 nucleotide base spacing. They control different metabolic 
and developmental pathways such as reproduction, carbohydrate metabolism, sexual 
differentiation and electrolyte balance [145-148]. ER has two subtypes- ERα and ERβ. Both 
proteins share similar regions with having a variable N-terminal region. Although they bind to 
similar DNA sequences, both proteins interact with different sets of proteins. Their tissue 
distributions are also different as well. Whereas ERα is more localized in major female organs 
like ovary, vagina, uterus, mammary gland etc. ERβ is found in ovary, prostate, spleen, testis, 
lung, thymus and hypothalamus [148].  PRs are expressed mainly in female reproductive tissues 
and central nervous system. Two isoforms of PR, named PR-A and PR-B are generated from two 
different promoters. PR-B is stronger as a transcription factor than PR-A.  They differ only in the 
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N-terminal region; however, they have their exclusive as well as common target genes. For 
example, PR-B works on the mammary gland development whereas PR-A works on uterus 
[149]. Similar to ER and PR, GR also resides in the cytoplasm with chaperones. GR mainly 
works in liver, pancreas, muscle and adipose tissues. 5 different GR protein subtypes - GRα, 
GRβ, GRγ, GR-A and GR-P arise due to alternative splicing of the mRNA [150]. GRα increases 
cell’s sensitivity to glucocorticoid hormone whereas GRβ decreases it. The MR is a 107KD 
protein which plays a major role in fluid transport and blood pressure control [151].  In addition 
to kidney, other organs also express MR and it is evident that MR acts on hippocampus, 
endothelium, heart as well. AR gene encodes a 110 KD protein and this protein binds to its 
cognate ligands, specially testosterone and 5-α-dihydrotestosterone. AR plays a major role in the 
development of male reproductive systems. AR presence has also been observed in female 
tissues including ovaries, uterus, skin, adipose and brain etc. [152].   
Type II receptors are the group of nuclear receptors that bind to and form heterodimer 
with 9-cis retinoic acid receptor (RXR). The receptor heterodimers bind to DNA elements of 
direct repeat with different spacing sequences. The binding partners of RXR include trans 
retinoic acid receptor (RAR), thyroid hormone receptor (TR), vitamin D receptor (VDR) and 
ecdosyne receptor (EcR). These receptors work both on endocrine and lipid sensing receptor 
pathways. They also serve as the sensor for metabolites [153].  Type II receptors also have some 
previously known orphan receptors. These partner receptors of RXR heterodimers were put in 
the orphan receptor family since their ligands were unknown. However, they are now called 
adopted orphan receptors since their ligands have been discovered [154, 155]. These receptors 
include peroxisome proliferator-activated receptors (PPARs), oxysterols (LXR), constitutive 
androstane receptor (CAR), bile acids (FXR).  PPARs mainly function in homeostasis in 
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development and inflammation as well as lipid sensing metabolism. Three major subtypes of 
PPAR have been identified: PPARα, PPARβ/δ and PPARγ [156, 157]. PPARα and γ are found in 
liver and adipose tissue, however, PPARβ/δ is found in almost all tissues. PPARα play a crucial 
role in cardiac lipid homeostasis by regulating the gene expression of fatty acid oxidation [156, 
157]. PPARγ functions to regulate systemic lipid and glucose level [158-160]. It has been 
observed that the mutation in PPARγ gene results in diabetes, insulin resistance and hypertension 
[161]. On the other hand, PPARδ works as a sensor for very low density lipoprotein in 
macrophages [162]. Liver X receptors (LXRα and LXRβ) regulate the cholesterol homeostasis 
and lipid metabolism in skeletal muscle. These receptors are generally known as the cholesterol 
sensor [163]. 
Type III receptors include mainly the orphan receptors whose ligands are still unknown. 
Typically they form a homodimer with each other.. On the other hand, Type IV receptors bind to 
the core site as monomers. Rev-erbα , Rev-erbβ and NGF-1β are the examples of this receptor 
family. They also take part in lipid homeostasis and skeletal muscle function [164].     
 
1.3.2 Domain structure of nuclear receptors  
During evolution, nuclear receptors have assumed different lengths due to sequence 
mutations. However, they follow a common pattern in terms of their domain structure [138, 165]. 
Typically, a nuclear receptor has six domains, they have been given the name of A to F domains 
from the N to C terminus. The A/B region is highly variable in receptors. The C domain is also 
called DNA binding domain (DBD). D domain is the hinge region that separates the E domain or 
the ligand binding domain (LBD) from the C domain. The LBD is followed by the variable F 
domain [166]. 
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The N terminal A/B region is very weakly conserved among species. This region can 
function autonomously as an activation function that binds to the co-activators [138] and hence 
also called activation function-1 (AF-1). However, their activity may also be regulated by 
ligands bound to the receptor as well. The most conserved domain of nuclear receptor is the 
DBD. As the name implies, DBD binds to specific sequences of the DNA called hormone 
response element (HRE). It has a length of 66 highly conserved residues consisting of two zinc 
finger motifs, two α-helices and a COOH extension [166]. The first zinc finger motif contains a 
region called the proximal box or P-box that controls the high affinity recognition of the HRE. 
The second zinc finger contains a distal box or D-box that determines the receptor dimerization 
and half-site spacing [138, 167]. Following the DBD, the D region is a poorly conserved region 
of the nuclear receptor. It serves as a hinge region between the DBD and LBD, thus allowing the 
two domains to adopt different conformation. It also contains a nuclear localization signal and 
may contain protein-protein interaction sites. The LBD is also a conserved region of the nuclear 
receptors, though it is not as strictly conserved as the DBD. Whereas the DBD mainly controls 
the binding of the receptor to the DNA, the LBD has multiple functions with its different small 
regions in it. It contains a dimerization region that mediates the dimer formation with another 
nuclear receptor’s LBD, followed by a ligand binding pocket for the lipophilic ligand. LBD also 
contains a co-regulator binding region with which it binds to either positive or negative 
coregulators, including the activation function-2 (AF-2). It is an α-helical domain which controls 
ligand dependent transcription and co-activator recruitment [166].  
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1.3.3 Mechanisms of nuclear receptor action  
Nuclear receptors got activated in three major steps. When the receptors are unliganded, 
they bind to a co-repressor molecules that have histone deacetylase (HDAC) activity. After the 
ligand binding, the co-repressor is dissociated from the complex and the receptor binds to co-
activators that have histone acetyltransferase activity (HAT) [167, 168]. The final step includes 
the interaction between co-activators and components of the RNA polymerase II complex to 
activate gene transcription [167].   
 
1.3.4 Vitamin D and vitamin D receptor  
Long before vitamin D was discovered, scientists understood with their experiences with 
diseases and diet that special organic micronutrients are required to prevent diseases like scurvy, 
rickets, beri-beri etc. [169]. It was Casimir Funk who first theorized that some food has “vital 
amine” in them which helps to maintain healthy life [170]. Later, it was discovered that a small 
water soluble molecule can prevent specific neurological diseases. Although not necessarily 
carrying amino group in them, scientists used the visionary idea of Funk and termed these factor 
as “Vitamin” [171, 172]. Soon after the first discovery, fat soluble molecules were also 
discovered and all of them were given the name of vitamin-A, B, C etc. Within a decade,   
another fat soluble molecule was discovered which could cure rickets in animal. This new 
vitamin was called, “vitamin D”. Since then, several chemicals have been given the name 
vitamin D (VD) as vitamin D1, vitamin D2, vitamin D3 etc. However, vitamin D1 was found to 
be an artifact and was later removed from the list [172].  Soon, it was also found that sunlight 
can cure rickets [173]. However, it was soon realized that sunlight actually helps producing 
vitamin D3 (VD3) in animal skin [174]. Therefore, VD3 is actually a pro-hormone, not a vitamin 
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in true sense. VD3 is formed with the help of sunlight from its precursor, 7-dehydrocholesterol in 
the skin. Later on, VD3 is hydroxylated in the liver and kidney to become 1, 25 
dihydroxyvitamin D3 (1,25D3), the active hormone. Although it was discovered that VD3 can 
improve bone mineralization and calcium absorption, directly adding VD3 to the VD3 deficient 
animal’s serum did not improve the bone mineralization. Therefore, it was assumed that 
something else carried the signal of VD3 to induce the cell for VD’s cellular activity [172]. Later 
it was discovered that VD3 acts through a receptor protein called vitamin D receptor (VDR) 
[175], a type II steroid nuclear receptor that forms a heterodimer with RXR for its function. As 
shown in Figure 4, VDR is comprised of four domains; the N-terminal DNA binding domain 
(DBD), a hinge region, the C-terminal ligand binding domain (LBD) and a small activation 
function-2 domain [176]. The DBD contains two zinc finger DNA binding motifs like other 
nuclear receptors. The hinge region allows VDR to adopt sufficiently different conformations 
through its flexibility [177].  
 
 
Figure 4: Domain structure of VDR 
VDR contains four distinct domains. The DNA binding domain (DBD), the hinge region, the 
ligand binding domain (LBD) and the co-activator binding domain. DBD and LBD each has a 
major phosphorylation site.  
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1.3.4.1 Co-regulators of VDR 
Previously, it was thought that nuclear receptors bind to their cognate ligands and execute 
their functions. However, it was soon revealed that the functional activity of these receptors rely 
much on the dimerization as well as other proteins. These proteins are called co-regulators [178]. 
As VDR has diverse functions in regulating gene expression, the capacity to work on regulating 
different genes relies on its ability to bind with diverse co-regulators. These co-regulators have 
VDR-interacting domains through which they bind to the DNA bound and ligand activated VDR 
protein to recruit other proteins and to stimulate or suppress transcription. They can also recruit 
other proteins with enzymatic activity, such as histone acetylase/deacetylase or RNA polymerase 
II. The first co-activator identified for VDR was steroid receptor co-activator-1(SRC-1) [179].  
CREB binding protein (CBP) and p300 were also found as VDR co-activators to stimulate the 
transcription of VDR responsive genes. On the other hand, VDR also recruit co-repressor 
proteins such as silencing mediator of thyroid and retinoid receptors (SMRT) and nuclear 
receptor co-repressor (NcoR), which can inhibit the expression of genes [180]. Such co-
repressors recruit histone deacetylase proteins that will repress the expression of target genes. 
However, there are also reports that these co-repressors do not associate with VDR as strongly as 
with other nuclear receptors [181].  
 
1.3.4.2 Post-translational modifications of VDR  
Like other proteins, VDR is also subjected to post-translational modifications and these 
modifications regulate VDR activity. In vitro and in vivo studies have shown that VDR gets 
phosphorylated at various sites. Whereas the phosphorylation at Ser-51 site by protein kinase C 
(PKC) negatively regulates VDR function [182], phosphorylation at Ser-208 position by casein 
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kinase II (CKII) enhances VDR transcriptional activity [183] . However, both positive and 
negative phosphorylations have been shown to be increased by stimuli given to cells. Therefore, 
the phosphorylations may be cell type specific. Other than phosphorylations, studies have also 
shown that plasma toxins from patients are able to bind to VDR and inhibit the VDR function by 
disrupting VDR-RXR heterodimer formation [184]. 
 
1.3.5 Mechanisms of VDR action  
Subcellular localization analyses have shown that VDR is mostly distributed in the 
nucleus. A small portion of VDR resides in the cytoplasm [185-187]. Upon active ligand 
(1,25D3) binding, conformational changes occur in VDR, which makes the ligand binding 
domain more accessible to RXR. RXR has several isoforms and VDR is known to bind with all 
of them [188]. Unliganded VDR may also bind to the DNA, but this binding is loose. The VDR-
RXR heterodimer is known to bind to the direct repeat 3 site where the recognition sequences or 
half sites are separated by three nucleotides. The VDR-RXR heterodimer then binds to 
transcription factor II protein as well as TATA binding protein to promote the formation of the 
preinitiation complex for transcription [189, 190]. To activate the gene expression, co-activators 
like SRC-1, CBP/p300 etc. are required. As previously discussed, these proteins have histone 
deacetylase activity which helps to unwind the DNA molecule and recruit RNA polymerase II to 
initiate transcription [189-191]. To repress gene expression, VDR-RXR can recruit co-repressors 
as previously described, which can deacetylate histones and stop the fromation of the 
preinitiation complex. Furthermore, the VDR-RXR heterodimer can also bind to the IL-2 
promoter and hinder the binding of the nuclear factor of activated T-cells (NFAT) transcription 
factor, thereby, repressing the transcription [192].   
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1.3.6 Chemical analogs of vitamin D 
1,25D3 plays a very important role in calcium homeostasis [193]. It has already been 
demonstrated that 1,25D3 can reduce the growth of cancer cells both in vitro and in vivo [194-
196]. Therefore, it can be used as a potential drug for chemotherapy. However, studies have 
shown that it can also induce hypercalcemia if administered to the patient regularly with doses 
required for chemotherapy [197].  Therefore, it is important to design and synthesize analogs of 
1,25D3 which will retain the therapeutic potential with less calcemic activity. Until now, 
thousands of chemical analogs of 1,25D3 have been developed [198]. However, only a handful 
of them seem to be usable as drug for human and animal use. The first set of analogs is 
alphacalcidol, doxercalciferol and dihydrotachysterol etc. [199, 200]. These drugs require further 
metabolic conversion to become fully active. A promising drug for hyperparathyroidism is 
maxacalcitol. It has much less side effect than 1,25D3 [201]. Seocalcitol or EB1089 has also 
become popular with in vitro experiments and have already been in the clinical trial to treat 
cancer patients [202]. This drug can inhibit growth and metastasis by inducing apoptosis in 
cancer cells [203]. Calcipotriol is another drug of the new generation which has been used to 
treat psoriasis [204]. It is also a promising drug for pancreatic cancer treatment [205].  
 
1.3.7 Non-genomic action of 1,25D3 
Due to the transcriptional and translational events exerted by 1,25D3 and VDR, the 
genomic response by the hormone is slow. However, 1,25D3 also induces nongenomic responses 
that occur quickly. Studies have shown that 1,25D3 can induce a fast formation of cAMP, 
calcium, and inositols. These secondary messengers molecules can activate Ca
2+
 channel. PKC, 
PKA, and MAPK pathways [206-210]. It can also induce rapid secretion of insulin by pancreatic 
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β cells by opening the Ca2+ and Cl− channel [211]. A recent study has shown that 1,25D3 can 
also induce exocytosis by Sertoli cells in testis [212].          
 
1.3.8 Vitamin D and cancer 
1,25D3 or calcitriol is known to play a major role in bone mineralization through 
maintaining the calcium and phosphate metabolism. Different factors like living places (in terms 
of altitude), food habit, and exposure to sun determine the levels of circulating vitamin D in 
blood or in tissue and according to these factors, a person can have sufficient vitamin D or can be 
vitamin D deficient [213-215]. It is worth mentioning that the measuring standard of vitamin D is 
the circulating 25(OH) vitamin D3, 25(OH)D3, in the blood serum. The set point of deficiency of 
25(OH)D3 is variable to different communities. The institute of medicine (IOM) sets the 
standard for deficiency as ≤20 ng per mL (50 nmol per L) and the endocrine society set the 
standard as 30 ng per mL (75 nmol per L) [216].  The deficiency determines the susceptibility of 
the person to bone related diseases like rickets. It is already known that a vast majority of people 
around the world, including those living in places with adequate sunlight, are vitamin D deficient 
[214]. Consequently, the prevalence of bone related diseases is also quite common. However, 
research works showed that vitamin D can also play an important role in preventing different 
diseases other than skeletal problems [217]. This is understandable because most cells in our 
body express VDR [218]. Therefore, vitamin D and VDR must have additional roles other than 
bone mineralization. 1, 25D3 has been reported to reduce the risk of diseases like hypertension, 
heart disease, neurological disease, diabetes, multiple sclerosis, asthma, autoimmune disease and 
more importantly, cancer [217].  
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The first in vitro study of the anticancer activity of 1,25D3 was shown by Colston et.al. 
This group showed that 1,25D3 can suppress the growth of malignant melanoma cells in culture 
[219]. Concurrently, another group also showed that 1,25D3 can differentiate mouse myeloid 
leukemia cells into macrophages [220].  Numerous studies have been done on the anticancer role 
of 1,25D3 and it is now established that it can suppress cancer growth both in vitro and in vivo 
[221-229]. Studies have shown that calcitriol or 1,25D3 can arrest breast cancer cell growth at 
G0/G1 stage by increasing the expression of p21, which can decrease the activity of cyclin 
dependent kinase activity. It has also been shown that EB1089 can decrease the expression of c-
myc oncogene at the mRNA level and aromatase expression by directly inhibiting the mRNA 
synthesis [224]. Although more potent in estrogen sensitive cell lines, 1,25D3 can also decrease 
the growth of estrogen insensitive cancer cells as well [230]. EB1089 in combination with 
tamoxifen have exhibited a synergistic effect on reducing breast cancer cell growth [231]. 
Therefore, a combination therapy may be a better treatment for breast cancer.  
1,25D3 is also known for its anti-inflammatory properties. Patients with acute or chronic 
inflammation have an increased propensity of developing prostate cancer [232]. Therefore, 
vitamin D might also play role in suppressing prostate cancer. Studies with prostate cancer cells 
have shown that 1,25D3 reduces the expression of proinflammatory cytokine like interleukine- 6 
(IL-6). 1,25D3 induces the expression of MAP kinase phosphatase 5, which inhibits p38 
activation by dephosphorylating p38 and ultimately decreases IL-6 production [233]. As IL-6 is 
directly involved in prostate cancer development, 1,25D3 treatment can hereby decrease prostate 
cancer progression. Furthermore, 1,25D3 analog BXL-628 inhibits prostate cancer growth and 
inflammation. This has already been tested positively in animal models as well [234]. 1,25D3 is 
known to modulate microRNA expression as well. In a recent study, combined treatments with 
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1,25D3 and testosterone of LNCaP prostate cancer cells, have shown that they can modulate the 
expression of fifteen microRNAs [235]. Upregulated micro-RNAs include miR-22, miR-29ab, 
miR-134, miR-1207-5p and miR-371-5p. These microRNAs target mRNAs with known 
fucntions in cell cycle progression, lipid synthesis and calcium homeostasis etc. In addition to the 
upregulation, this treatment also downregualted the expression of micro-RNAs like miR-17 and 
miR-20a, which are known as oncogenic micro-RNAs that promotes tumor progression.  
Therefore, combination of androgen and 1,25D3 can be an effective chemotherapy for prostate 
cancer patients. In addition, the expression of miR-100 and miR-125-b are downregualted. In 
previous studies, these two miRNAs are demonstrated to have a tumor suppressive role [236]. In 
vivo treatment of prostate cancer patients with 1,25D3 also changed the levels of these micro-
RNA, thereby showing a promising role of 1,25D3 as an orally administrable drug to treat 
prostate cancer patients [237]. 
The role of vitamin D in suppressing ovarian cancer mortality rate has also been reported 
[238]. Further studies showed that vitamin D can play an important role in ovarian cancer 
prevention [239]. A randomized study to link single nuclear polymorphism and vitamin D 
deficiency related ovarian cancer susceptibility revealed that low circulating vitamin D is 
associated with increased risk of ovarian cancer [240]. Studies have also shown that daily intake 
of vitamin D could reduce the risk of incidence and death by ovarian cancer [214].  
Our published studies in ovarian cancer have shown that 1,25D3 inhibits cancer growth 
by arresting cells at specific cell cycle checkpoints [194, 241, 242]. Further analyses have 
demonstrated that 1,25D3 induces microRNA target genes to decrease telomerase expression for 
cell death induction [196, 243] and to inhibit leptin and estrogen-induced tumor growth [195], 
suggesting that 1,25D3 has a particular role in lowering obesity-associated cancer risks in 
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women. More recent studies have shown that ovarian cancer invasion is suppressed by 1,25D3 
through the cooperated actions of epithelial and stromal VDR [244]. Overall, these studies 
project VDR as a new therapeutic target for ovarian cancer intervention.  
 
1.4 Central hypothesis  
The main objective of this project is to investigate how 1,25D3 and TNFα crosstalk to 
control cell death pathways and how the cell death programs can be developed to benefit cancer 
intervention. Our central hypothesis is that, 1,25D3 and TNFα can regulate each other’s cell 
death signaling pathway through a novel VDR-RIPK1 complex. This hypothesis has been 
formulated based on our preliminary data that 1,25D3 downregulated NF-κB regulated gene 
expression and that both TNFα and RIPK1 decreased VDR activity. Co-immunoprecipitation 
analyses showed that VDR and RIPK1 formed a protein complex, which was inducible by 
necroptotic stimuli. The rationale for the proposed research is, once it is known how 1,25D3 and 
TNFα regulate each other’s signaling, new and innovative approaches can be developed to 
improve cancer therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 
 
 
CHAPTER 2: 
MATERIALS AND METHODS 
 
2.1 Chemicals and antibodies 
Anti-Flag antibody (F7425), anti-Flag M2 affinity gel (A2220), fetal bovine serum (FBS) 
(12306C), MG132 (C2211), and protease inhibitor cocktail (11836170001) were purchased from 
Sigma-Aldrich (St. Louis, MO).  Anti-HA antibody (PRB-101P) was from Covance (BioLegend, 
San Diego, CA). Anti-VDR (C-20, D-6), anti-α-actinin (H-2, sc-17829) and anti-β-actin  (AC-
15, sc-69879) antibodies were from Santa Cruz Biotechnology  (Santa Cruz, CA). Anti-RIPK1 
antibody (BD 610458) was from BD Bioscience (San Jose, CA). Luciferase substrates were from 
Promega (Madison, WI).  The ECL Western blotting substrates were from Thermo Scientific 
(Waltham, MA).  Penicillin and streptomycin (30-002-CI) solution was from Corning 
(Tewksbury, MA). Lipofectamine 2000 (11668-019) and trypsin (25200-056) were from Life 
Technologies (Grand Island, NY). Etoposide was from Sigma, Smac Mimetic (SM) was from 
Chemietek. (Indianapolis, IN). 1,25D3 (calcitriol) and necrostatin-1 (Nec-1) was purchased from 
Calbiochem (La Jolla, CA). 1,25D3 was reconstituted in 100% ethanol (EtOH) and Nec-1 in 
DMSO. Both stock solutions were stored at −20 °C. Handling of 1,25D3 and Nec-1 was 
performed under indirect lighting. Concentrations of 1,25D3 varied in each experiment and have 
been stated in the figure legends. 
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2.2 Plasmids  
Control and RIPK1 shRNA plasmids (pRS-MIG-HRS and pRS-MIG-RIP193, 
respectively) were kind gifts from Dr. Martin Leverkus of University of Heidelberg [245]. The 
RIPK1 K45M mutant vector was kindly provided by Dr. Junying Yuan of Harvard 
University[68]. The p23 VDR reporter containing rat 24-hydroxylase promoter in 
pMAMMneoLuc  was provided by Dr. H. F. Deluca of the University of Wisconsin-Madison 
[246]. RIPK1 K377R mutant was kindly provided by Dr. Zhijian Chen of the University of 
Texas Southwestern Medical Center at Dallas [60]. HA-RIPK1, Flag-RIPK1, HA-VDR and 
Flag-VDR plasmids were generated by cloning full length RIPK1 and VDR cDNA into HA- and 
Flag-tagged pcDNA3.1 vectors, respectively. Deletion constructs of VDR and RIPK1 were 
generated by PCR and cloned into HA-tagged pcDNA3.1 and Flag-tagged pCMV vectors, 
respectively. All primer sequences have been shown in tables 1, 2 and 3.  
 
2.3 Cell lines 
293T and L929 cells were purchased from American type culture collection (ATCC) 
(Manassas, VA). RIPK1 wild type and null mouse embryonic fibroblasts (MEFs)  were kindly 
provided by Dr. Junying Yuan of Harvard University [247]. PE01 and PE04 cells were kindly 
provided by Dr. Toshiyasu Taniguchi of Fred Hutchinson Cancer Research Center [248]. Mouse 
mammary tumor VDR wild type and null cells were kindly provided by Dr. JoEllen Welsh from 
State University of New York, University at Albany [249].  VDR+/- and VDR-/- MEFs were 
from Dr. Jun Sun from University of Illinois at Chicago [250]. PE01, PE04, TykNu, TykNuR, 
M41 and M41R cells were maintained in RPMI medium containing 2 mmol/L L-glutamine, 100 
U/mL penicillin, 100 μg/mL streptomycin, and 10% FBS. OVCAR3 cells were maintained in 
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RPMI medium containing 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 15% FBS. All other cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/ml streptomycin, 
and 10% FBS. 
 
2.4 Stable knockdown of RIPK1  
For stable knockdown of RIPK1, PE01 and OVCAR3 cells were plated in a 60mm dish. 
At 70-80% confluency, cells were transfected with 5μg of  pRS-MIG-HRS (HRS: hyper random 
sequences) control or pRS-MIG-RIPK193 plasmid. Forty-eight hours post-transfections, stable 
clones were selected in media containing 2 μg/mL puromycin. Cells were maintained in 
puromycin containing medium for two to three weeks. Single colonies were picked knockdown 
clones. RIPK1 knockdown in stable clones was verified by Western blot analyses.  All cells were 
maintained in a 37°C humidified incubator with 5% CO2.  Both pRS-MIG-HRS control and 
pRS-MIG-RIPK193 constructs were a kind gift of Dr. Martin Leverkus, University of 
Heidelberg as mentioned previously. 
 
2.5 Immunological analyses  
For co-immunoprecipitations, 293T cells were plated in 60mm dishes. For simplicity, one 
co-immunoprecipitation experiment detail is given here.  At 60%-70% confluency, 293T cells 
were transfected with 1.5 μg of Flag-tagged VDR and HA-tagged RIPK1 (for example). 48 hours 
post-transfection, cells were washed with ice-cold phosphate buffered saline (PBS) and were  
lysed in cell lysis buffer containing 20 mM Tris-HCL (pH 7.5), 150 mM NaCl, 1% (v/v) NP-40, 
1 mM PMSF and protease inhibitor cocktail. After two consecutive 6-second sonications 
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separated by brief cooling, cells were kept on ice for 10 minutes before centrifugation. Cellular 
extracts were incubated overnight at 4°C with M2 antibodies conjugated with beads. For co-
precipitations of endogenous VDR and RIPK1, L929 cells were cultured in 100mm dishes in 
DMEM medium. Cells were lysed with lysis buffer containing 25 mM Tris•HCl pH 7.4, 1% NP-
40, 150 mM NaCl, 1 mM EDTA, 5% glycerol.   Protein concentration was measured through 
Bradford assay and 2μg of cellular protein was incubated with 1μg of anti-VDR antibody (Santa 
Cruz; C-20 antibody) overnight at 4°C, followed by a  4-hour incubation with protein G beads. 
Rabbit IgG antibody was used as a negative control. After incubations, the beads were washed 
five times with lysis buffer and precipitated proteins were detected by Western blot analyses.  
 
2.6 Transfection and reporter assays 
2×10
5
 293T cells were plated in 12-well plates and transfected with plasmids the next 
day. For example, to perform luciferase assay with p23 VDR reporter plasmid, 293T cells were 
transfected with 200 ng of p23 VDR reporter plasmid, 20 ng of pCMVβgal, 50 ng of Flag-VDR 
and indicated amounts of Flag-RIPK1. Twenty-four hours post-transfections, cells were treated 
with either EtOH or 1,25D3 for an additional 24 hours. After the incubation, cells were washed 
with ice-cold PBS and 200μl of 1X lysis buffer was added to each well to lyse the cell. The 5X 
lysis buffer contained: 125mM Tris-phosphate (pH 7.8), 10mM 1,2-diaminocyclohexane-
N,N,N’,N’-tetraacetic acid, 50% glycerol and 5% Triton X-100. 5mM of DTT was added to the 
final lysis buffer solution. Cells were sonicated twice for 6 seconds and were centrifuged at 
13,000 rpm for 15 minutes. 25μl of the lysate was used to measure the luciferase activity and 
100μl of the lysate was used to measure β-galactosidase activity.  Luciferase activity was 
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measured by adding luciferase substrate from Promega (E1501) and normalized with cognate β-
galactosidase activity. Each data point was analyzed in triplicates (n=3). 
 
2.7 Cytoplasmic and nuclear fractionation 
For cytoplasmic protein extraction, cells were washed and scraped with ice-cold PBS. 
After pelleting, cells were re-suspended in lysis buffer (10 mM Hepes, pH7.9; 10 mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA) and kept on ice for 15 minutes. 10% NP-40 was added and 
followed by centrifugation for 1 minute at 14,000 rpm. The supernatant was collected as 
cytoplasmic protein. The pellet was washed with ice-cold PBS, re-suspended in nuclear 
extraction buffer (20 mM Hepes, pH 7.9; 400 mM NaCl, 1 mM EDTA, 1 mM EGTA), and kept 
on ice for 30 minutes with 3- to 5-second vortexing at 5-minute intervals. After centrifugation at 
14,000 rpm for 5 minutes, the supernatant was collected as nuclear extracts.  
 
2.8 Necroptotic cell death induction  
Cells were plated in 96-well plates and left overnight for attachment. Next day, day 0 
reading value was measured after MTT treatment and rest of the cells were treated with TNFα 
(10ng/ml), Etoposide (100μM), SM (1μM), z-VAD (5μM), Nec-1(20μM) alone or in 
combination for 16 hours in respective experiments unless otherwise stated. Cell growth 
suppression was measured by MTT assays.  
 
2.9 Methylthiazol tetrazolium (MTT) assays   
Cell growth was quantified using MTT assays. Cells were plated in 96-well plates and 
treated with either EtOH or 1,25D3 for 6 days. MTT assays were performed as described [251]. 
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In brief, MTT was added to wells at a final concentration of 0.5 mg/mL and incubated for 3 
hours. The media were removed after the incubation and 200 μl of DMSO was added to the 
wells. The absorption at 595 nm was measured in a MRX microplate reader (DYNEX 
Technologies, Chantilly, VA). . Six samples were analyzed in parallel for each data point (n=6). 
 
2.10 Necroptotic study in mice  
VDR+/− mice of C57B16 background (The Jackson Laboratory, Bar Harbor, ME) were 
mated to produce VDR+/+ (WT)  and VDR−/− (KO) mice [244]. Only VDR-WT and VDR-KO 
male mice were used for this study. 8-14 weeks old mice were injected intravenously through 
tail-vein with murine TNFα (Peprotech) 450μg/kg per mouse. Core body temperature of mice 
was measured before and after injection by a lubricated rectal thermometer probe purchased 
from Kent Scientific. Mice with temperature below 23.6°C was sacrificed due to ethical reason. 
All procedures were reviewed and approved by the Institutional Animal Care and Use 
Committees at the University of South Florida.  
 
2.11 Statistical analyses 
Significant analyses were performed with the Student t-test. All values were presented as 
mean ± standard deviation (SD) with the number of observations (n) indicated in the figure 
legends. p <0.05 was considered to be statistically significant. 
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Table 1: Primers used for cloning  
Primer name Sequence 
VDR-F GAGGGATCCATGGAGGCAATGGCGGCCAG 
VDR-R GAGCTCGAGTCACTGGAAGGAGAGGCAGCGGT 
RIPK1-F GAGAGATCTATGCAACCAGACATGTCCTT 
RIPK1-R GAGGTCGACTTAGTTCTGGCTGACGTAAA 
 
Table 2: Primers used for VDR deletion analyses  
Primers Domain Sequence 
VDR-full 
length- F 
Full 
length 
GAGGGATCCATGGAGGCAATGGCGGCCAG 
VDR-full 
length- R 
Full 
length 
GAGGTCGACGGAGATCTCATTGCCAAACA 
N-VDR- F:  DNA 
binding 
domain 
GAGGGATCCATGGAGGCAATGGCGGCCAG 
N-VDR  R:  DNA 
binding 
domain 
GAACTCGAGTCACATCATGTCTGAAGAGGTGA 
C-VDR  F:  Ligand 
binding 
domain 
GAGGGATCCATGGACTCGTCCAGCTTCTCCAA 
C-VDR  R:  Ligand 
binding 
domain 
GAGGTCGACGGAGATCTCATTGCCAAACA 
∆AF2-F                 GAGGGATCCATGGAGGCAATGGCGGCCAG 
∆AF2-R                GAGGTCGACCTGGAAGGAGAGGCAGCGGT 
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Table 3: Primers used for RIPK1 deletion analyses 
Primers name Domain Sequence 
RIPK1-FL F: FL GAGGAATTCATGCAACCAGACATGTCCTT 
RIPK1-FL R:  FL  GAGGTCGACTTAGTTCTGGCTGACGTAAATC  
KD-RIPK1  F:  KD GAGGAATTCATGCAACCAGACATGTCCTT 
KD-RIPK1  R:  KD  GAGGTCGACTCAATAAAAAGGCCTAAATTTTTCT 
KD+IDs-RIPK1  F: KD+IDs GAGGAATTCATGCAACCAGACATGTCCTT 
KD+IDs-RIPK1  R: KD+IDs GAGGTCGACTCACATATAATTGTAGGCTCCAATC 
KD+ID-RIPK1  F: KD+ID GAGGAATTCATGCAACCAGACATGTCCTT 
KD+ID-RIPK1  R: KD+ID GAGGTCGACTCACGTCAGACTAGTGGTATTATC 
ID-RIPK1 F:  ID GAGGAATTCTATTTAAGTCAATTAGAAGA 
ID-RIPK1  R:  ID GAGGTCGACTCACGTTCACGTCAGACTAGTGGTATTATC 
∆KD-RIPK1  F:  ∆KD   GAGGAATTCTATTTAAGTCAATTAGAAGA 
∆KD-RIPK1  R:  ∆KD   GAGGTCGACTTAGTTCTGGCTGACGTAAATC 
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CHAPTER 3: 
RESULTS 
As aforementioned in the introduction section, several cancers respond to 1,25D3 for 
growth suppression, including ovarian cancer. However, not all ovarian cancer cells responded to 
1,25D3 for growth suppression in our studies. This suggests the existence of additional 
molecular determinants which can suppress 1,25D3 action. We have examined the role of RIPK1 
in 1,25D3 action and report that RIPK1 is a transcriptional inhibitor of VDR and decreases 
1,25D3-induced growth suppression. Interestingly, VDR inhibition occurred independently of 
RIPK1 kinase activity and was likely mediated through a RIPK1-VDR protein interaction that 
increased the cytoplasmic retention of VDR.   
 
3.1 RIPK1 inhibits VDR transcriptional activity independent of its kinase activity   
To test the effect of RIPK1 on VDR, HEK293T cells were transfected with a luciferase 
reporter construct containing rat 24-hydroxylase promoter in pMAMMneoLuc [246] together 
with plasmids encoding VDR and RIPK1 and treated with a vehicle (Ethanol) or 1,25D3. The 
transcriptional activity of VDR was measured by luciferase assays. 1,25D3 simulated luciferase 
activity and the co-expression of RIPK1 substantially reduced its capacity to do so in a dose 
dependent manner (Fig. 5A, bar graphs). RIPK1 did not decrease VDR protein abundance (Fig. 
5A, lower panels) and thus apparently decreased the specific activity of VDR. To validate the 
data, we repeated the same experiment with another reporter construct containing VDRE-TK-luc 
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promoter. RIPK1 also decreased VDRE-TK-luc promoter activity (Fig.5B, bar graphs). In this 
case too, RIPK1 did not decrease VDR expression (Fig.5B, lower panel). Therefore, RIPK1 
decreased that activity of VDR irrespective of the VDR promoter type. 
Since RIPK1 is a protein kinase, we next sought to determine whether the enzymatic 
activity of RIPK1 is required for the inhibition of VDR. As shown in Fig. 6 (bar graphs), the 
kinase-dead K45M RIPK1 mutant inhibited 1,25D3-induced VDR activity to the same extent as 
wild-type RIPK. The addition of RIPK1 kinase inhibitor Nec-1 did not relieve the inhibition. In 
the absence of ectopic RIPK1, Nec-1 slightly elevated the activity of VDR, accompanied by a 
similar increase in the levels of VDR protein expression (Fig 6, lower panels). In our studies, 
Nec-1 increased the expression levels of both wild-type RIPK1 and the K45M mutant and both 
wild-type RIPK1 and the kinase-dead mutant increased the levels of VDR protein expression. 
The increased expressions of RIPK1 and VDR by Nec-1 and RIPK1, respectively, were 
consistently observed in our studies. To confirm that VDR is not a target of RIPK1 kinase 
activity, in vitro kinase assay was performed whereas VDR was used as a substrate of RIPK1 
protein. Although RIPK1 phosphorylated myelin basic protein (MBP) as a positive control, it did 
not phosphorylate VDR (Fig. 7A).   In addition to the RIPK1 mediated VDR activity decrease, 
we also wanted to determine the effect of TNFα on VDR activity. As shown in Fig. 8, TNFα 
alone also decreased the activity. Since HEK293T cells have endogenous RIPK1, TNFα may 
have worked through the RIPK1 that was already in the cell. However, addition of RIPK1 also 
decreased the VDR luciferase activity and RIPK1 combined with TNFα treatment had an 
additive effect to decrease the activity. Both TNFα and RIPK1 increased VDR level (Fig. 8, 
lower panel), confirming that the decrease of VDR activity was not due to the loss of VDR 
protein. 
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Overall, the studies suggest that RIPK1 inhibits the transcriptional activity of VDR 
independent of its kinase activity.  
 
3.2 RIPK1 forms a protein complex with VDR 
As aforementioned, RIPK1 can perform biological functions through its enzymatic 
activities or as an adaptor. The evidence of RIPK1’s ability to inhibit VDR activity is 
independent of its kinase activity prompted us to ask whether RIPK1 forms a complex with 
VDR. HEK293T cells were transfected with plasmids encoding tagged RIPK1, VDR or both and 
co-immunoprecipitation experiments were performed. M2 anti-Flag beads co-precipitated HA-
RIPK1 with Flag-VDR (Fig. 9A) and HA-VDR with Flag-RIPK1 (Fig. 9B) from cells expressing 
both proteins but not either protein alone. Thus, RIPK1 associates with VDR in overexpression 
studies.  The binding of RIPK1 to VDR was detected both in the absence and presence of 1,25D3 
but its amount was reduced by the hormone treatment (Fig. 10).  Moreover, the complex 
formation also occurred between endogenous VDR and RIPK1 in L929 mouse fibroblast cells 
(Fig. 11), ruling out the possibility that the complex formation might be an artifact of ectopic 
overexpression.   
 
3.3 The complex formation between RIPK1 and VDR involves the kinase domain of RIPK1 
and the ligand-binding domain of VDR 
To define the site in VDR that mediates RIPK1 binding, VDR deletion constructs (Fig. 
12) were generated and their ability to bind to RIPK1 was assessed by co-immunoprecipitation 
analyses. As shown in Fig. 13, the VDR fragment deleted of the N-terminal DNA binding 
domain and hinge region bound to RIPK1 whereas the fragment deleted of the C-terminal ligand   
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Figure 5: RIPK1 decreases VDR activity  
293T cells were transfected with 20 ng of pCMVβgal, 50 ng of Flag-VDR and indicated amounts 
of Flag-RIPK1 and A) 200 ng of p23 VDR reporter plasmid or B) 200 ng of VDRE-Tk-Luc 
VDR reporter plasmid,. The next day, cells were treated with either EtOH or 1,25D3 for 24 
hours. Luciferase activity was determined and normalized with cognate β-gal activity. Each data 
point was analyzed in triplicates (n-3) and reproduced two times. Western blot analyses were 
performed with antibodies as indicated. 
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Figure 6: Suppression of VDR activity by RIPK1 is kinase-independent  
293T cells were transfected with 200 ng of p23 VDR reporter plasmid, 20 ng of pCMVβgal, 50 
ng of Flag-VDR and either with wild-type (RIPK1-WT) or kinase-dead mutant (RIPK1-K45M) 
RIPK1 and treated with 1,25D3 and/or RIPK1 inhibitor Nec-1 (20 μM). Luciferase activity was 
determined and normalized with cognate β-gal activity. Each data point was analyzed in 
triplicates (n-3) and reproduced two times. Western blot analyses were performed with 
antibodies as indicated. 
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Figure 7: RIPK1 does not phosphorylate VDR 
A. Flag-RIPK1 was transfected in H2K293T cells and expressed RIPK1 was immunoprecipitated 
with anti-Flag antibodies. In vitro kinase assay was performed with His-tag-VDR as a substrate. 
Myelin basic protein (MBP) was used as a positive control.  B. Coomasie blue imgae to show 
VDR expression. 
 
binding domain failed to bind, showing LBD as the site for RIPK1 binding. The VDR fragment 
deleted of the activation function 2 (AF2) region retained the ability to associate with RIPK1 
(Fig. 13), revealing expendability of the AF2 region for binding. Using a similar approach, the 
regions in RIPK1 required for VDR interaction were also defined by deletion analyses. A set of 
RIPK1 deletion constructs were generated (Fig. 14) and their ability to form complexes with 
VDR was determined in co-precipitation analyses. As shown in Fig. 15, neither the kinase nor 
the intermediate domain alone was co- precipitated with VDR whereas the fragment containing 
both regions was co-precipitated. 
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Figure 8: TNFα also suppresses VDR activity 
293T cells were transfected with 200 ng of p23 VDR reporter plasmid, 20 ng of pCMVβgal and 
indicated amounts of Flag-VDR and Flag-RIPK1. 24 hours post-transfection, cells were treated 
with either EtOH or 1,25D3 with or without TNFα for another 24 hours. Luciferase activity was 
determined and normalized with cognate β-gal activity. Each data point was analyzed in 
triplicates (n-3) and reproduced two times. Western blot analyses were performed with 
antibodies as indicated.  
 
The analyses suggest that, although the kinase or intermediate domain alone is not 
sufficient, they both are required for binding to VDR. The deletion of C-terminal death domain 
and the region between RHIM and the death domain did not abolish the VDR binding, showing 
that these regions are expendable.  
Overall, the binding analyses tell us that RIPK1 employs multiple domains to interact 
with the LBD of VDR. Although the ability of RIPK1 to repress the transcriptional activity of 
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VDR is independent of its enzymatic activity, the kinase domain is physically involved in the 
complex formation.    
 
 
 
Figure 9: RIPK1 forms a protein complex with VDR 
In reciprocal immunoprecipitation, 293T cells were transfected with A) 1.5 μg of Flag-tagged 
VDR and HA-tagged RIPK1 and B) 1.5 μg of Flag-tagged RIPK1 and HA-tagged VDR as 
indicated. 48 hours posttransfection, cell extract were immunoprecipitated  with Flag antibodies 
followed by immunoblotting with indicated antibodies. 
 
3.4 VDR-RXRα complex was not affected by RIPK1  
Since VDR forms a heterodimer with RXRα, we sought to determine whether RIPK1 
binding with VDR influenced the VDR-RXRα complex formation or not. Co-precipitation of 
VDR along with RXRα in absence or presence of RIPK1 showed that RIPK1 did not change the 
VDR-RXRα complex formation (Fig. 16). In both cases, 1,25D3 increased the binding, showing 
that RIPK1 did not decrease the binding even in presence of the hormone, either.  
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Figure 10: RIPK1-VDR complex formation is decreased by 1,25D3 treatment 
293T cells were transfected with 1.5 μg of Flag-tagged VDR and HA-tagged RIPK1 as indicated. 
24 hours posttransfection, cells were treated either with EtOH or 10
-7 
nM 1,25D3 for 6 hours. 
Cellular lysates were immunoprecipitated with anti-Flag antibody conjugated beads. Western 
blot analyses were performed with indicated antibodies. 
 
3.5 RIPK1 increases VDR retention in the cytoplasm 
  In an effort to understand the mechanisms underlying VDR repression by RIPK1, we 
next assessed the effect of RIPK1 on VDR cellular localization. As shown in Fig. 17A, the VDR 
protein ectopically expressed in 293T cells was mainly localized to the nucleus but the co-
transfection of RIPK1 increased the cytoplasmic VDR signal. Due to the positive effect of 
ectopic RIPK1 on the overall levels of VDR expression, the impact of ectopic RIPK1 on the 
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Figure 11: Interaction of endogenous VDR and RIPK1 in L929 cells 
Whole cell lysates of L929 cells were immunoprecipitated with anti-VDR antibody followed by 
Western blot analyses with anti-VDR and RIPK1 antibodies as indicated. 
 
nuclear VDR was not obvious from the Western blots (Fig. 17A). However, after quantification 
with ImageJ and normalization with cognate whole cell signals, it became clear that the 
increased VDR retention in the cytoplasm was accompanied by a decrease in the nuclear VDR 
(Fig. 17B, bar graphs).  The data argue that the increased cytoplasmic retention is the possible 
mechanism underlying the VDR repression by RIPK1. Next, we sought to determine how the 
hormone influenced the retention of VDR into the cytoplasm by RIPK1. We performed the same 
experiment but treated with or without 1,25D3 for 24 hours post-transfection. The cytoplasmic 
and nuclear localization protein expression of VDR and RIPK1 (Fig. 18B) compared with the 
whole cell expression (Fig. 18A) showed there was more VDR retention in the cytoplasm than 
the nucleus in presence of RIPK1 and this was not relieved by 1,25D3 treatment (normalized in 
Fig. 18C, bar graphs).  This data further proved the previous finding that RIPK1 indeed retained 
VDR into the cytoplasm. 
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Figure 12: Schematic representation of different VDR deletion constructs  
The different deletion constructs of Flag tagged-human VDR used in this study. Amino acid 
residue numbers are shown at the top of the graphs. ΔC: C-terminal LBD deleted (aa.1-203); ΔN: 
N-terminal DNA binding domain and hinge region deleted (aa.204-427); ΔAF-2: Helix-12 
deleted (aa.1-408). 
 
 
 
Figure 13:  RIPK1 binds to the C-terminal LBD of VDR 
293T cells were transfected with 1.5 μg of HA-RIPK1 together with 1.5 μg of Flag-tagged full-
length (FL) VDR or its deletion constructs as indicated. Cellular extracts were subjected to co-
immunoprecipitation analyses with antibodies as indicated. 
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3.6 Depletion of RIPK1 expression increases sensitivity of cells to 1,25D3-induced growth 
suppression 
So far, we have shown that ectopic RIPK1 repressed VDR by binding to and holding the 
receptor in the cytoplasm. If this is true, depletion of RIPK1 expression should potentiate 1,25D3 
action and increase the sensitivity of cells to the growth suppressive effect of the hormone. 
Indeed, in comparison to wild-type MEFs, RIPK1-null MEFs exhibited a dramatic and 
significant increase in their sensitivity to 1,25D3-induced growth suppression at all 
concentrations tested (Figs.19A and 19B).   
 
 
Figure 14: Schematic representation of different RIPK1 deletion constructs 
Schematic representation of the domain structure of HA-RIPK1 and its deletion constructs. 
Amino acid residue numbers are shown at the top of the graphs. KD: kinase domain (aa.1-289); 
ID: Intermediate domain (aa.290-583); IDs: Smaller ID (aa.290-547); ΔKD: Kinase deleted 
(aa.290-583). 
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Figure 15: Multiple regions of RIPK1 mediate its binding to VDR 
293T cells were transfected with 1.5 μg of Flag-VDR together with 1.5 μg of full-length (FL) or 
deletion constructs of HA-RIPK1 as indicated. Cellular extracts were subjected to co-
immunoprecipitation analyses with antibodies as indicated.  
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Figure 16: VDR-RXRα binding is not decreased by RIPK1 
293T cells were transfected with Flag-tagged RXRα, GFP-tagged VDR and HA-tagged RIPK1 
as indicated. 24 hours posttransfection, cells were treated with EtOH or 1,25D3 and after 24 
hours of the treatment, cell extracts were immunoprecipitated  with Flag antibodies followed by 
immunoblotting with indicated antibodies. 
 
Consistent with the data from RIPK1-null MEFs, RIPK1 knockdown by stable shRNA 
expression in OVCAR3 (Figs. 20A and 20B) and PE01 (Figs. 21A and 21B) ovarian cancer cells 
also significantly increased their sensitivity to 1,25D3-induced growth suppression. The ability 
of RIPK1 depletion to potentiate the growth response to 1,25D3 was observed in multiple cell 
types with a stable shRNA pool (Fig. 20B) and two independent clones (Fig. 21B), ruling out the 
potential artifact of clonal effects and stable selection with antibiotics.  
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Figure 17: RIPK1 increases VDR cytoplasmic localization 
A) 293T cells were transfected with Flag-VDR and Flag-RIPK1 constructs. Thirty-six hours 
post-transfections, cells were treated with EtOH or 10
-7
 nM 1,25D3 for 6 hours. Whole cell, 
cytosolic, and nuclear extracts were prepared and subjected to Western blot analyses with 
indicated afanantibodies. Anti-α-tubulin and PARP-1 Western blots were included as loading 
controls for cytoplasmic and nuclear proteins, respectively. B) The intensity of Western blot 
bands in figure 17 A was quantified by ImageJ (NIH). VDR signals were first normalized with 
cognate loading controls. Cytoplasmic and nuclear VDR were further normalized with 
corresponding whole-cell VDR and plotted as relative VDR signals. 
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Figure 18: RIPK1 increases VDR cytoplasmic localization in the presence of 1,25D3  
1,25D3 treatment increases VDR localization in presence of RIPK1. 293T cells were transfected 
with Flag-VDR and Flag-RIPK1 constructs. Thirty-six hours post-transfections, cells were 
treated with EtOH or 10
-7
 nM 1,25D3 for 6 hours. A) Whole cell, B) cytosolic and nuclear 
extracts were prepared and subjected to Western blot analyses with indicated antibodies. Anti-
HSP60 and PARP-1 Western blots were included as loading controls for cytoplasmic and nuclear 
proteins, respectively. C) The intensity of Western blot bands in figure 18B was quantified by 
ImageJ (NIH). VDR signals were first normalized with cognate loading controls. Cytoplasmic 
and nuclear VDR were further normalized with corresponding whole-cell VDR and plotted as 
relative VDR signals.  
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Overall, the growth analyses with RIPK1-depleted cells support the conclusion of 
transfection studies that RIPK1 is a VDR repressor. The studies argue that RIPK1 depletion may 
represent an effective strategy for increasing the potency of 1,25D3 and its analogs in cancer 
intervention. 
 
3.7 VDR-RIPK1 form endogenous complex in response to necrotic cell death induction  
Overexpression data in HEK293T cell lines showed the VDR-RIPK1 complex formation. 
However, this complex may not be observed at the endogenous level in this cell line since 
HEK293T has very low level of VDR expression. Therefore, we sought to induce L929 cells as 
our model cell line for endogenous VDR-RIPK1 binding (Fig.11).  This cell line is routinely 
used to show complex formation by RIPK1 protein with cell death induction [76] . We first 
treated L929 cells with TNFα, SM or MG132 (proteasome inhibitor) individually or in 
combination for 4 hours. After the treatment, cell lysates were immunoprecipitated with VDR 
antibody followed by western blot.  Neither of the drugs could induce VDR-RIPK1 complex 
alone, whereas the combined treatment of all three drugs could induce the binding (Fig. 22A). 
This finding also led us to think using etoposide as alternative drug of SM.  We  performed the 
same cell death induction experiment combining TNFα and etoposide with or without MG132. 
Here, a time based treatment showed that the complex formation was induced by TNFα, 
etoposide and MG132 combined (Fig. 22B). The complex formation was stronger with time and 
formed only when MG132 was used. This suggests that VDR-RIPK1 complex is also formed by 
cell death induction at the endogenous level and may be proteolytically degraded.  
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Figure 19:  RIPK1 depletion sensitizes MEFs to 1,25D3 
A) RIPK1+/+ and RIPK1-/- MEF cells were plated into 100mm dishes. Cell lysates were 
subjected to Western blot to detect the RIPK1 in both cells with anti-RIPK1 antibody. B) MEFs 
were plated in 96-well plates and treated with either EtOH or indicated concentrations of 1,25D3 
for 6 days. MTT assay was performed. Six samples were analyzed in parallel for each data point 
(n=6) and the experiment was repeated twice. Percentages of cell growth were first calculated by 
subtracting MTT values at day zero from those in day 6 followed by dividing with day zero 
values. Percentages of growth suppression by 1,25D3 were calculated by dividing percentages of 
cell growth in 1,25D3-treated groups with those of the EtOH controls. **p<0.005; ***p<0.001, 
****p<0.0001.  
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Figure 20: Knockdown of RIPK1 increases 1,25D3 induced growth suppression in 
OVCAR3 cells 
A) RIPK1 and VDR expression was determined by Western blot analyses in an OVCAR3 cell 
pool stably expressing control or RIPK1 shRNA. B) The OVCAR3 control and RIPK1 KD cells 
were treated with EtOH or 1,25D3 for 6 days and the percentage of growth suppression was 
measured in MTT assays as in figure 19B.  
 
  
 
65 
 
 
 
 
Figure 21: Knockdown of RIPK1 increases 1,25D3 induced growth suppression in PE01 
cells 
A) RIPK1 and VDR expression was determined by Western blot analyses in PE01 cell clones 
stably expressing control or RIPK1 shRNA. B) PE01 clones were treated with EtOH or 1,25D3 
for 6 days and the percentage of growth suppression was determined in MTT assays as in figure 
19B. 
 
3.8 VDR-RIPK1 complex may be degraded by proteasome pathways 
As discussed in the introduction section, RIPK1 protein has Lysine 377 residue in the 
intermediate domain (ID) which is a major ubiquitination site. The K48 ubiquitination targets the 
protein for proteasomal degradation. Since the ID is also important for binding to VDR along 
with its kinase domain (KD); it may pose an important question whether the ubiquitination 
influences the binding or not. For this kind of study, ubiquitin mutant has been used where the 
lysine residue has been modified to other residue such as arginine so that  it can no longer be 
ubiquitinated [60]. If RIPK1-VDR complex is ubiquitinated at the K377 site and further targeted 
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for proteasome degradation, the K377R ubiquitin mutant of RIPK1 should show a stronger 
binding with VDR than the wild type. This study can alternatively supported by the use of a 
proteasome inhibitor MG132. MG132 targets the proteasome inhibitor complex and inhibits its 
activity. Addition of MG132 should rescue the wild type RIPK1-VDR complex formation from 
degradation and will not change mutant RIPK1-K377R-VDR complex formation. Since our 
endogenous binding between VDR and RIPK1 suggested that VDR-RIPK1 complex may be 
subjected to proteasomal degradation, we sought to determine whether mutation in K377 site of 
RIPK1 also supports this finding. To determine whether RIPK1–VDR complex gets 
ubiquitinated followed by degradation, we transfected 293T cells with HA-VDR along with Flag 
tagged  wild type RIPK1 or  flag tagged mutant RIPK1-K377R constructs. As shown in Fig. 23, 
RIPK1 ubiquitin mutant construct showed more binding with VDR. In addition to that, although 
MG132 substantially increased the complex formation of VDR with wild type RIPK1, it did not 
change as much in case of mutant RIPK1. This suggests that VDR-RIPK1 complex may get 
ubiquitinated and degraded by proteasome pathway. 
 
3.9 VDR may potentiate necroptosis in mammary tumor cells 
It is already known that cytokines can stimulate both prosurvival and prodeath signals 
[100]. Their selection on stimulating either pathway depends upon cell type or other stimulants. 
For example,  TNFα treatment on L929 cells induces necroptotic cell death [252]. On the other 
hand, etoposide  or SM can change the prosurvival signaling of TNFα  into prodeath signaling 
[100]. Both of these drugs inhibit or deplete cIAPs from cells, rendering RIPK1 mediated 
apoptotic or necroptotic cell death pathway [100]. As caspase mediated apoptotic cell death can 
be blocked by pan caspase inhibitor z-VAD, the RIPK1 mediated apoptotic or necroptotic cell 
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Figure 22: Endogenous binding of VDR-RIPK1 forms upon cell death induction 
A) L929 cells were treated with murine TNFα, SM and MG132 alone or in combination as 
indicated for 6 hours. B) L929 cells were treated with murine TNFα(10ng/ml), 
Etoposide(100μM) and MG132(10μM) in combination for different time period as indicated. 
Aliquots of 1.5mg of cell lysates were immunoprecipitated with anti-VDR (D-6) antibody. The 
levels of RIPK1 and VDR in the immunocomplex and in the cell extracts were determined by 
Western blot analysis.   
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Figure 23: RIPK1-VDR complex may get degraded by proteasome  
293T cells were transfected with 1.5 μg of HA-tagged VDR and either RIPK1-WT or ubiquitin 
mutant RIPK1-K377R (Flag-tagged). 44 hours posttransfection, cells were treated with either 
DMSO or 10μM MG132 for 4 hours. Cell extracts were immunoprecipitated with Flag 
antibodies followed by immunoblotting with indicated antibodies. 
  
death can still occur through RIPK1 mediated pathway. To understand the role of VDR in 
apoptotic or necroptotic cell death pathway, we induced VDR wild type and VDR null mouse 
mammary tumor cells (MMT-VDR-WT and MMT-VDR-KO, respectively) with murine TNFα 
and etoposide alone or in combination for 16 hours to induce cell death. As shown in Fig. 24A, 
TNFα or etoposide alone did not suppress cell growth; however, combination of those two drugs 
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substantially suppressed growth in MMT-VDR-WT cells. On the other hand, MMT-VDR-KO 
cells did not show much growth suppression. z-VAD along with TNFα and etoposide could not 
relieve the WT cells from growth suppression, indicating that the suppression was not occurring 
through caspase-8 mediated pathway. Interestingly, Nec-1 almost prevented the cell death in WT 
cells. This indicates that, VDR is required for TNFα and etoposide mediated cell death and it 
may occur through necroptotic pathway. As SM also depletes IAP level, we performed the same 
experiment using SM instead of etoposide. Fig. 24B shows that MMT-VDR-WT cells responded 
the same way as Fig. 24A. Therefore, it might be concluded that VDR may potentiate RIPK1 
mediated necroptotic cell death in mouse mammary tumor cells.  
 
3.10 VDR role in necroptosis is cell line specific 
Mouse embryonic fibroblast (MEF) cell line is an important candidate in cell death 
processes. As this cell line contains endogenous RIPK3 [76], it can be used as an ideal candidate 
for necroptosis study. To validate our findings in an epithelial cell line like the mammary tumor 
cells, we sought to determine how the presence or absence of VDR responded to necroptotic cell 
death. We have used VDR heterozygous (VDR+/-) MEF cell line as an alternative to VDR-WT 
MEF. As shown in Fig. 25, MEF cell line responded to the opposite manner of MMT cell line. 
Here, VDR null MEF cell line responded to necroptotic cell induction much more than VDR +/- 
MEF cell line. One explanation might be mammary tumor cells are epithelial cells, whereas MEF 
cells are mesenchymal cells. Therefore, the response of VDR to necroptotic induction was cell 
line specific.      
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Figure 24: MMT-VDR null cells are not responsive to necroptosis 
Mouse mammary tumor VDR wild type and VDR null cell lines, MMT-VDR-WT and MMT-
VDR-KO, respectively cells were plated onto 96 well plate. 24 hours later, cells were treated 
with TNFα (10ng/ml), etoposide (100μM) (Fig. A), Smac mimetic (SM) (1μM) (Fig. B), z-
VAD(10μM), Nec-1(10μM) alone or in combination as indicated, for 16 hours. Cell growth 
suppression was measured by MTT assay. Six samples were analyzed in parallel for each data 
point (n=6) and the experiment was repeated twice.  
 
3.11 VDR does not modulate RIPK1-RIPK3 complex formation  
As RIPK1 and RIPK3 form a complex that is important in necroptotic cell death, we sought to 
determine whether VDR decreases or increases the RIPK1-RIPK3 complex formation by binding 
to it. HEK293T cells were transfected with RIPK1, RIPK3 and VDR containing respective tags. 
Immunoprecipitaiton followed by western blot showed that the RIPK1-RIPK3 complex 
formation did not change due to the presence of VDR (Fig. 26). However, with our experience 
on coimmunoprecipitation analyses, RIPK1-RIPK3 complex seemed much stronger than RIPK1-
VDR complex. Therefore, ectopic expression data might not reflect the endogenous influence of 
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VDR on RIPK1-RIPK3 complex formation. Hence, it may be required to repeat the experiment 
in endogenous protein level. 
 
 
 
 
Figure 25: The involvement of VDR in necroptosis appears cell line specific 
VDR heterozygous and VDR null mouse embryonic fibroblast (VDR+/-MEF and VDR-/-MEF, 
respectively) cells were plated onto 96 well plate. 24 hours later, cells were treated with TNFα 
(10ng/ml), SM (1μM), z-VAD (10μM), Nec-1(10μM) alone or in combination as indicated, for 
16 hours. Cell growth suppression was measured by MTT assay. Six samples were analyzed in 
parallel for each data point (n=6) and the experiment was repeated twice. 
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3.12 RIPK1 expression varies between platinum sensitive and resistant cell lines 
The problem with chemotherapeutic drugs even after first successful chemotherapy is that, the 
patient becomes chemoresistant within months. It is more prevalent in ovarian cancer [253]. To 
determine the effect of RIPK1 expression in platinum sensitive and resistant cancer cell lines, we 
utilized three pairs of ovarian cancer cisplatin sensitive and resistant cancer cell lines. Sensitive 
cell lines were TykNu, PE01, M41 and their resistant counterpart cell lines were TykNuR, PE04, 
M41R, respectively. We first performed a western blot to see whether there is any differential 
pattern of expression of RIPK1 among the sensitive and resistant cancer cell lines. Interestingly, 
cisplatin resistant cell lines showed either slight (TykNuR, M41R) or significantly (PE04) 
increased expression of RIPK1 compared to their cisplatin sensitive counterpart cell line (Fig 
27). This suggests that during the process of gaining resistance to the drug, these cell lines also 
had more RIPK1 expression. This also potentiates the fact that RIPK1 may work in cancer cell 
survival.  
 
3.13 VDR deletion defer mice death by necroptotic shock in vivo 
As the role of VDR in necroptotic induction is cell line specific, it is important to determine the 
role of VDR in necroptosis in vivo. A well-established test for necroptotic induction in mice is 
injecting mTNFα through tail-vein injection [88, 117] (Fig. 28). This induces systemic 
inflammatory respiratory syndrome (SIRS) and septic shock in mice. SIRS happens due to 
systemic inflammation. The final outcome of the treatment is severe hypothermia and death 
[117]. To know whether VDR plays a role in inducing necroptosis in vivo or rather protects mice 
from it, we injected mTNFα in C57BL6 VDR wild type and null mice through tail-vein injection. 
VDR wild type mice suffered necroptotic shock and started dying within 2 hours of mTNFα 
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Figure 26: RIPK1-RIPK3 in vitro binding does not get affected by VDR  
293T cells were transfected with 1.5 μg of Flag-tagged RIPK1, HA-tagged VDR and Myc-
tagged RIPK3 as indicated. 48 hours posttransfection, cell extract were immunoprecipitated  with 
Flag antibodies followed by immunoblotting with indicated antibodies. 
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Figure 27: RIPK1 level is increased in platinum resistant ovarian cancer cell lines 
Cisplatin sensitive ovarian cancer cell lines, TykNu, PE01, M41 and their resistant counterpart 
cell lines TykNuR, PE04, M41, respectively were cultured in 100mm dish. Cell extracts were 
immunoblotted to measure the expression level of RIPK1. 
 
injection and continued to show the response afterwards. On the other hand, VDR null mice 
showed delayed response to mTNFα (Fig. 29). Although VDR deletion could not fully rescue the 
mice from necroptotic shock, it could delay the death more than VDR wild type mice (at 8 hours, 
p=0.0148).  
 
 
 
Figure 28: Procedure of necroptotic induction in mice and temperature measurement 
Mice are injected mTNFα intravenously through tail-vein injection. A rectal probe attached with 
a thermometer is used to measure the core-body temperature. 
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Figure 29: VDR deletion delays necroptotic induction in mice 
Kaplan-Meier survival plot of C57BL/6 male VDR wild type (n=7) or null mice (n=8). Mice 
were injected with mTNFα (450μg/kg, Peprotech) intravenously through tail-vein injection. Core 
body temperature was measured through indicated time period for the next 48 hours. Mice with 
temperature below 23.6° were euthanized for ethical reasons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*8 hrs, p= 0.0148 
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CHAPTER 4 
DISCUSSION 
 
Our lab has previously shown that 1,25D3 regulates signaling pathways mediated by cell 
death ligands [254]. Therefore, it is perceivable that the downstream effector proteins of 1,25D3 
and cell death ligands may cross-talk with each other. RIPK1 is well established as an essential 
molecule involved in mediating cell survival and death mechanisms. In this study, we have 
defined a novel function for RIPK1 in nuclear receptor action by identifying it as a VDR 
repressor. Reporter analyses on two different VDR promoter constructs have first shown that 
RIPK1 inhibits the transcriptional activity of VDR. Further studies also showed that this 
inhibition was independent of its kinase activity. Subsequent co-precipitation analyses have 
revealed that RIPK1 forms a complex with VDR, and deletion analyses defined the interaction 
interface to the LBD of the receptor. Interestingly, the kinase domain of RIPK1 appears to be 
required for its binding to VDR, even though its kinase activity is expendable for VDR 
repression. While the molecular mechanisms underlying VDR repression by RIPK1 remains 
largely to be defined, our studies suggest that increased cytoplasmic retention of VDR may be 
part of the picture. More importantly, RIPK1-knockout or knockdown increased the sensitivity of 
cells to 1,25D3-induced growth suppression, demonstrating the significance and clinical 
relevance of the knowledge gained in our mechanistic studies. Overall, our studies suggest that 
the depletion of RIPK1 may be an effective way to increase the sensitivity of cancers to 1,25D3 
and its analogs.  
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Our studies have clearly demonstrated that VDR repression by RIPK1 occurs 
independently of its kinase activity and is mostly likely mediated through its adaptor function as 
a VDR-interacting protein. Although our data suggest that the increased cytoplasmic retention of 
VDR by RIPK1 binding as part of the mechanisms underlying VDR suppression, it should be 
noted that the nuclear localization signals have been identified in the DNA-binding domain and 
hinge region of VDR, whereas RIPK1 binding was mapped to the LBD (Fig.13). On the other 
hand, nuclear exporting signals have been located to the LBD of VDR.  It is thus perceivable 
that, RIPK1 might promote VDR nuclear export. The issue is that RIPK1 is a cytoplasmic 
protein and we have not detected nuclear RIPK1 in our studies, making it less likely for RIPK1 
binding to directly promote the nuclear export of VDR. Nevertheless, our mapping analyses 
suggest that multiple regions of RIPK1 are involved in its binding to VDR. It is possible that, 
after the primary contact with the LBD is made, RIPK1 may interrupt the interaction between 
VDR and nuclear pore structures through steric hindrance by secondary contacts with other 
regions in VDR. Besides hormone binding, the LBD is also known to be involved in mediating 
interactions between VDR and cofactors. Thus, RIPK1 binding may cause VDR repression not 
only by increasing VDR retention in the cytoplasm, but also by interfering with the recruitment 
of transcriptional cofactor. One possible explanation of VDR downregulation by RIPK1 is 
through the inhibition of the formation of VDR-RXR heterodimer, since RXR binds to VDR 
through the C-terminal LBD. However, our data showed that RIPK1 did not interfere with the 
VDR-RXR binding. Hence, other transcriptional activator or repressor might have played a role 
in VDR activity suppression by RIPK1.  
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A large amount of epidemiological and molecular studies have shown that vitamin D 
reduces cancer risk and that 1,25D3 analogs are promising agents for cancer treatment. However, 
the potential of 1,25D3 and its analogs in cancer intervention has yet to be realized in clinics. A 
majority of the published studies about vitamin D and cancer have been dedicated to pathways 
through which the hormone suppresses cancer growth and invasion; very little is known about 
the molecules and pathways that suppress VDR action and cause resistance of cancer cells to 
1,25D3 and its analogs. The presented studies suggest that the expression of RIPK1 may cause 
resistance to 1,25D3-induced growth suppression and identify RIPK1 as a molecular target for 
increasing the therapeutic potential of 1,25D3 analogs for cancer. The fact that VDR suppression 
is not mediated by the kinase activity of RIPK1 makes it more challenging to target RIPK1 for 
cancer intervention. However, technological advancements in small interference RNA and gene 
editing tools could make it possible to develop strategies for targeted depletion of RIPK1 in 
cancer.  
Studies have also shown that RIPK1 is subjected to ubiquitination [60, 255]. Our data 
showed that the complex formation between VDR and the ubiquitin mutant of RIPK1 (RIPK1-
K377R) was stronger than VDR and wild type RIPK1 (Fig. 23). This was also supported by our 
endogenous binding data in L929 cells. Cell death induction by TNFα and etoposide/SM showed 
increased endogenous binding in presence of proteasome complex inhibitor MG132 (Fig. 22A 
and 22B).  Therefore, our date clearly indicated that VDR-RIPK1 complex is subjected to be 
degraded after formation. This might be postulated that proteasome complex can recognize this 
complex and degrade it by ubiquitination to keep the cell alive. 
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The VDR-RIPK1 complex appeared to be regulated by necroptotic stimuli and we have 
detected a cell line specific effect of VDR on necroptosis (Figs.24A and B, 25). However, more 
extensive studies are needed to explain the results from different cell lines that appear to be 
conflicting. It should be mentioned that necroptotic stimuli can also lead to RIPK1 mediated 
apoptotic cell death, in case if RIPK3 is not expressed in the cell line [100]. Therefore, to 
confirm the role of VDR in necroptosis in both MMT-VDR and VDR-MEF cell lines, further 
experiments are required. Downstream effect of necroptotic induction such as phosphorylation of 
RIPK3 and MLKL as well as time lapse video microscopy through staining of RIPK1-RIPK3 
complex have not been done in our study. Therefore, these experiments might be done in future 
to confirm the role of VDR in necroptotic cell death in these cell lines.  
While the presented studies have focused on the effect of RIPK1 on VDR action and 
1,25D3-induced growth suppression, the complex formation between RIPK1 and VDR suggest 
that VDR and its ligand may regulate RIPK1 functions. We first assumed that VDR interaction 
with RIPK1 may interfere with RIPK1-RIPK3 complex formation. However, our overexpression 
data does not indicate that VDR disrupts RIPK1-RIPK3 binding (Fig. 26). This should be noted 
that RIPK1-RIPK3 binding may be stronger than VDR-RIPK1 complex and hence, is not visibly 
getting affected. This experiment was done in overexpression system and should also be done in 
endogenous system to see whether VDR can disrupt the RIPK1-RIPK3 binding or not. MEF cell 
line is a good candidate to show RIPK1-RIPK3 complex formation through necroptotic 
induction. Therefore, VDR+/- and VDR-/- MEF cell lines can be used to see whether VDR 
interferes with RIPK1-RIPK3 complex formation at the endogenous level. Stable expression of 
VDR in VDR-/- MEF cell line can confirm the finding in this experiment.  
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   In the current study, we have also shown the in vivo role of VDR role in necroptosis. 
Established in vivo studies of TNFα induced necroptosis employs tail-vein injection of TNFα. 
This causes a rapid core body temperature due to SIRS, which shows necrotic cell death in mice. 
Our study showed that although VDR in cell death assays showed differential role depending 
upon the cell line, VDR is actually required to induce necroptosis in vivo. Despite the fact that 
VDR deletion could not completely inhibit TNFα induced necroptotic death in mice, the VDR-
KO mice survived longer than VDR-WT mice. This underscores the role of VDR in inducing 
necroptotic induction in vivo.   
Our comparative expression study in cisplatin sensitive and resistant cells showed that 
RIPK1 is differentially expressed in cells. We also observed that RIPK1 level in those platinum 
resistant cell lines was slightly increased. Whether RIPK1 level also increased during the process 
of drug resistance can also be worth exploring. Ovarian cancer in most of the patients is detected 
at the advanced stage when the tumor has already metastasized to other organs. The role of 
RIPK1 in both cell survival and cell death pathway makes it an ideal candidate for testing this 
protein to play any role in cancer cell survival in chemotherapy. Recent studies show that RIPK1 
is required in cancer cell survival and downregulation of RIPK1 in those cells increases 
chemotherapeutic response [101, 103]. Our present study suggests that knockdown of RIPK1 
increases 1,25D3 induced cancer cell growth suppression. While we did not perform any cell 
death assay after cisplatin or carboplatin treatment on these RIPK1 knockdown cancer cells, our 
work can also be extended to chemotherapeutic efficacy on these cells. It may be also studied 
whether the combined treatment of 1,25D3 and platinum drugs have any additive or synergistic 
effect on RIPK1 knockdown ovarian cancer cells.  
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4.1 Summary and perspective 
Our data allow us to draw the following conclusions. 1) RIPK1 decreases VDR activity 
and the suppressive action does not depend on its kinase activity of RIPK1;  2) RIPK1 binds to 
VDR, specifically the binding is mediated by the kinase and intermediate domain of RIPK1 and 
the C-terminal ligand binding domain of VDR; 3) RIPK1 retains VDR into the cytosol and 
controls the nuclear translocation of VDR both in absence and in presence of 1,25D3; 4) 
Depletion of  RIPK1 in cancer cell increases 1,25D3 mediated cell growth suppression; 5) The 
role of VDR in necroptotic cell death is cell line specific. 6) VDR deletion decreases 
necropototic inflammation in vivo in mice.  
Based on the above conclusions, future studies should focus on the investigation of the 
following observations for their potential significance in understanding 1,25D3 actions in cancer 
and potential clinical relevance.  
First, although it has been shown that RIPK1 decreased VDR activity by inhibiting 
nuclear translocation, the mechanism is not fully understood yet. It has not been studied yet 
whether RIPK1 also cross-talks with transcriptional coactivators or corepressors of VDR. 
Detailed mechanistic study is required to answer questions such as whether RIPK1 can also 
squelch SRC-1 to the cytoplasm to contribute to the inhibition of VDR activity.  
Secondly, the cross-talk between VDR and RIPK3 may be possible in cell survival and 
death signaling through RIPK1. Whereas RIPK1 was present in all cell lines that we have 
studied, RIPK3 expression has not been tested (Fig 27). RIPK3 expression study can also be 
done in these cell lines to find out potential relationship between platinum resistance and RIPK3 
expression. Our overexpression data showed that VDR did not interfere with RIPK1-RIPK3 
binding (Fig 26). However, this study was done in overexpression system where abundant 
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proteins were present to bind with each other and in HEK293T cell line, which is nonresponsive 
to necroptotic induction. Therefore, studies with endogenous proteins in cell lines and in VDR-
WT and null MEFs need to be performed to see whether VDR affects RIPK1-RIPK3 interaction 
during necroptotic cell death. Restoring VDR expression in VDR-null MEF can be used to 
confirm the role of VDR in necroptosis.  
Lastly, our studies appear to corroborate with the previous findings that RIPK1 is an 
oncogenic protein and that downregulating RIPK1 increases the chemosensitivity of cancer cells. 
In our studies, we have shown that RIPK1 knockdown also increased 1,25D3 mediated cell 
growth suppression in ovarian cancer cell lines. This can be further tested in other vitamin D 
sensitive cancer cell lines. Along with this, the sensitivity of ovarian cancer cells to therapeutic 
drugs can be tested in our RIPK1 knockdown cells. As for the 1,25D3 sensitivity, it is worth to 
find out whether combined treatments of 1,25D3 and other chemotherapeutic drugs have more 
profound effects, additive or synergistic, on suppressing cancer cell growth in RIPK1 
knockdown cells.   
In summary, my thesis work is the first to demonstrate an interaction between RIPK1 and 
VDR. The studies suggest that inhibiting RIPK1 expression can be an effective strategy to 
potentiate the effects of 1,25D3 in suppressing tumor growth. Together with RIPK1 depletion, 
1,25D3 treatments may become an important component of standard cancer therapy in clinics.  
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